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Although the use of split thickness skin grafts (STSGs) is the gold standard to cover 
excised deep burns, relatively little is known about how regenerating dermal connective 
tissue underneath the STSGs affects wound healing and ultimately the outcome from 
grafting.  
We compared three ways to treat a wound bed of a deep burn after excision onto 
fascia. The recipient sites before transplanting the STSGs were: a plain excised wound as 
a control, a site treated with permanent artificial dermal template (Integra®), and a site 
with granulation tissue promoted by cellulose sponge (Cellonex™). 
In study I ten adult burn patients with deep burns covering 22-45 % of total body 
surface-area were included. Test areas were divided into three equal sections (5 x 10 cm 
each) that were covered in random order with one of the aforementioned materials. After 
two weeks, the artificial dermal template and the wound bed under the viscose cellulose 
sponge were also covered with STSGs. At each site the wound healing process was 
followed-up for up to one year. Histological analysis from punch biopsy samples and 
clinical scar assessments were performed using the Vancouver Scar Scale at 3 and 12
months.  
Study II concentrated on the healing process of STSGs one week and 3 months after 
grafting from the material retrieved from study I. Healing was assessed using 
immunohistochemistry of late inflammation, angiogenesis/vascularity, and proliferation .   
In study III, samples from study I were analysed using proteomics. The differentially 
expressed proteins (DEPs) were further analysed using Ingenuity Pathway Analysis. 
Based on the results of pathway analysis the potential role and function of DNAH10 (a 
motor protein usually found in cilia and flagella) was assessed in a group of patients with 
psoriasis as well as healthy controls.  This thesis has five main findings: 1) A valuable 
experimental model was designed for objective comparative studies of different treatment 
modalities with-in a patient-controlled study protocol.  2) In study I, inflammation was 
more distinctive in the granulation tissue promoted by cellulose sponge. In contrast to 
expectations, more pronounced inflammation combined with granulation tissue formation 
did not jeopardize the outcome in terms of scarring problems when the wound bed was 
covered in a timely fashion. 3) After one year, the clinical outcome and the histological 
findings of the artificial template site did not differ from the two other test sites. 4) In 
study III, at one-year follow-up, approximately 12% of all proteins detected demonstrated 
differential expression across comparisons between the different wound bed treatments, 
and 5) the biggest differences were found in the expression of the axonemal heavy chain 
dynein DNAH10. STSGs on pre-treated wound beds demonstrated higher expression of 
DNAH10 than STSGs of control sites. The expression of DNAH10 was also higher in 
intra-lesional psoriasis skin samples than non-lesional or healthy control skin samples.  
The dermal composition of the wound bed has an impact on cellular behaviour during 
wound healing, and it affects functions such as proliferation and angiogenesis. 
Surprisingly by the end of the follow-up period, healthy granulation tissue resulted in as 
little scarring as dermal substitute in the STSGs. Despite the lack of clinical and 
histological differences with those assessment methods used, clear differences were found 




Large deep burns are devastating life-threatening injuries, however patient survival has 
increased during the past decades. Early excision combined with emerging new 
technologies in tissue engineering show promising results, also reducing the morbidity of 
the patients. Yet, a substantial deficiency remains regarding the basic knowledge of wound 
healing of burns and the effect of different types of wound covers at the cellular, protein, 
and molecular levels. One of the most challenging issues in the future will be to improve 
the quality of remaining scars to closely resemble healthy skin.  
Patients can suffer from disfiguring scars, limited range of motion of the affected area, 
pain, and itching. In addition to physical symptoms the scars cause also psychosocial 
problems. Improving the quality of the scars has a tremendous impact on the quality of life 
and on daily life activities of the patients. 
Skin substitutes may improve the outcome both functionally and cosmetically. Severe 
burns with a limited amount of healthy skin for grafting have also prompted a need to 
search for other alternatives to cover the wounds either temporarily or permanently. 
The clinical use of skin substitutes is continuously increasing. Even though there is a
substantial amount data on the products from laboratory testing, with both cell-culture and 
animal testing, and an increasing number of case reports and descriptive studies, there is 
an obvious deficit in comparative systematic human studies due to difficulties in finding 
similar wounds with similar etiologies and similar circumstances. Therefore, a large deep 
burn wound offers a good model for research with a possibility to divide the wound bed 
into comparative areas.  
The primary goal of temporary wound covers is to protect the wound from microbial 
invasion and from further injury, whereas permanent skin replacements also restore the 
barrier function from inside-out. Autologous options to cover the wound are not always 
possible. When the condition of the wound bed or the general condition of the patient do 
not allow definitive wound closure, temporary and/or less invasive options are considered. 
Commercially available wound care products and dressings range from passive dressings 
to interactive products, even with cells. As the technology in tissue engineering progresses 
it becomes more difficult to differentiate between wound dressings and skin substitutes. 
Even when the products are integrated to the wound bed they are usually replaced by 
autologous tissue in the long run. These innovations benefit also wound and skin-cancer 
patients with larger defects (after operation), since dermal substitutes can be used in both 
patient groups. 
Wound healing is a complex long-standing process with overlapping different phases 
from injury of the tissue to mature scar. Many factors affect the healing process and 
contribute to the final outcome. This thesis addresses some clinical, cellular, and even 
molecular-level questions on wound healing; the role of regenerating dermal connective 
tissue composition in intricate interaction between epidermal, dermal, and even bone 
marrow derived mesenchymal stem cells; and the long-term outcome of healed split 




 REVIEW OF THE LITERATURE  2.
2.1 FUNCTION AND STRUCTURE OF SKIN 
Skin is the outmost boundary to the external world that envelops the human body. It 
protects the body from various physical, chemical, and biological insults such as UV
radiation; penetration of toxic substances and microbial invasion from the environment; 
and it controls fluid movement preventing dehydration. Skin also functions as a sensory 
organ and takes part in thermoregulation and it has metabolic functions, for example by 
producing vitamin D (1). 
Skin consists of three layers: epidermis, dermis, and hypodermis or subcutis. 
Epidermis is mainly responsible for the barrier function, primarily in stratum corneum
serving as a water-tight layer (2), whereas dermis provides tissue tensile strength, 
resilience, elasticity, blood vessels, and innervation. These two layers are connected to 
each other by a special extracellular matrix, basement membrane (BM) (3,4). Since 
epidermis is avascular, its’ nurturing and oxygen supply are provided by diffusion from 
dermal vessel plexus. Underneath the dermis a subcutis containing adipose tissue and 
connective tissue attaches the skin to underlying structures like muscle fascias, functioning 
as cushion and insulation, and storing energy (5). 
2.1.1 EPIDERMIS 
Epidermis consists of several layers of cells, mainly (approximately 90%) of 
keratinocytes (6). Other cells include melanin pigment producing melanocytes, Merkel 
cells as mechanoreceptors, and immune cells such as Langerhans cells (LC), antigen 
presenting dendritic cells (DC) (7), and epidermal T-cells (DETCs). 
In the innermost layer, basal keratinocytes attach to the basement membrane. They 
form a population of interfollicular stem cells that proliferate and ensure the continuity 
and sufficiency of cells for barrier maintenance. They maintain their own population, but 
mostly remain in a relatively quiescent state and rarely dividing (6). In addition to 
interfollicular stem cells, three other epidermal stem cell niches serve as keratinocyte 
reservoirs: the epidermal appendages in the hair follicle bulge, in the base of sebaceous 
glands and in the eccrine sweat glands (8-10). These stem cells are the reserve of 
epidermal cells in case of injury and they become activated during wound-healing and 
repair. Epidermal stem cells regulate epidermal maintenance (11) and cellular 
homeostasis. During normal maintenance the cells are renewed by asymmetrical division 
of interfollicular stem cells. Upon division, stem cells produce transit-amplifying 
progenitors: one daughter cell remains on the basal layer, whereas the other daughter cell 
is destined to differentiate (12). Transit-amplifying cells divide rapidly a few times and 
then commit to terminal differentiation. When entering the terminal differentiation 
process, keratinocytes lose contact with the basement membrane and exit the cell cycle. 
Differentiation progresses from the suprabasal spinous cells to the lamellar granule-
containing granular cells. In the late differentiation stage, a cornified cell envelope forms 
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and a bricks-and-mortar-like structure is generated from cross-linked corneocytes and 
lamellar body lipids secreted into the intercellular space generating a waterproof barrier 
(13). The outmost layer of epidermis forms of flat collapsed cornified dead keratinocytes, 
corneocytes, and extracellular lipids, cholesterol, free fatty acids, and ceramides (13). 
Barrier function 
Stratum corneum prevents passive diffusion of water. Beneath the stratum corneum
tight junctions seal the intercellular space between epidermal cells. Tight junctions are 
composed of transmembrane proteins that are linked to cytoskeletal actin (14). Crosslinks 
between molecules of involucrin, loricrin, filaggrin, and small protein proline-rich 
molecules of cornified envelopes of granular cells make this layer tear resistant. These two 
physical barriers, stratum corneum and tight junctions in stratum granulosum, together 
prevent the penetration of harmful substances from outside and escape of fluids from 
inside (15). 
Epidermis also has immunological functions. Lipids, especially free fatty acids, 
antimicrobial peptides such as beta-defensins and cathelicidins, and antimicrobial proteins, 
create an antimicrobial barrier. Barrier breach provokes production of antimicrobial 
peptides (16,17). During wounding, stressed keratinocytes rapidly induce transcription of 
keratins KRT16/17-KRT6. Langerhans cells (LCs), members of the dendritic 
cell/macrophage family located under the tight junction barrier, take part in a variety of T-
cell responses. They recognize and process soluble antigens (18). 
Wounding causes acute breeches in barrier function, while chronic inflammatory 
conditions, such as psoriasis, lead to chronic impairment or decrease of barrier function. 
Deficiencies of different compounds of upper epidermal layers lead to barrier 
disturbances. 
Keratins 
Keratins are cytoskeletal intermediate filaments of keratinocytes adding mechanical 
stability. Keratin links with desmosomes and hemidesmosomes create a network 
enhancing mechanical resilience in the tissue. Keratins in the upper epidermis are formed 
into the cornified epithelial barrier layer. Keratins form paired complexes of type I and 
type II keratins. In skin, keratin pairs KRT5 and KRT14 are expressed in the basal cell 
layer, whereas keratins KRT10 and KRT1 are expressed in differentiated keratinocytes in 
the suprabasal layers. Keratin pairs KRT16 and KRT6 are expressed in highly activated 
and proliferative suprabasal keratinocytes during wound healing and in stressed 
keratinocytes in skin pathologies, and KRT16 serves as a marker for hyperproliferation 
(19). Typically K6, K16, and K17 are rapidly induced as a result of various challenges to 
the interfollicular epidermis like wounding and infection, in response to oxidative or UV 
stress, as well as in chronic hyperproliferative diseases, such as psoriasis and cancer (20-
22). Keratins are also involved in cell signaling. See chapter 2.2.3 on cell signaling. 
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2.1.2  BASEMENT MEMBRANE  
Basement membrane (BM) is a special type of extracellular matrix attaching epidermis 
to dermis (3), but also functionally separating them. BM functions as a selective 
permeability barrier, acts as a gatekeeper for trafficking of the cells, and regulates cell 
growth. Together with BM-associated growth factors, structural proteins such as laminin 
and type IV collagen promote cell proliferation. BM takes part in cell signaling and 
thereby regulates cell survival and cell death (23,24). BMs create a biochemically and 
physically distinct environment (25) and modulate stem cell behavior by driving them to 
differentiate or to maintain their stemness (26). 
Structurally, the BM of skin consists of two independent polymeric networks, one of 
laminin and the other of type IV collagen as major constituents, which are attached to each 
other by perlecan, a heparan sulfate proteoglycan (27). Basal keratinocytes and dermal 
fibroblasts produce BM components in co-operation. Most of the BM molecules are 
produced by both cell types, but laminin 5 is synthetized only by keratinocytes and 
nidogen only by fibroblasts (28). 
Type IV collagen stabilizes and protects the BM from mechanical stress. In addition, 
laminins initiate BM formation, mediate early cell differentiation, and support migration 
by functioning as cell adhesion molecules (29). Laminin is also an important component 
of hemidesmosomes, and it interacts with integrins on cell surfaces as well as with 
integrins on type VII collagen of anchoring fibrils providing protection from shear forces. 
2.1.3 DERMIS 
Dermis provides pliability, elasticity, and tensile strength to skin. In addition to 
extracellular matrix (ECM), dermis contains fibroblasts, endothelial cells, smooth muscle 
cells, pericytes, neurons, immune cells such as different types of T cells, mast cells, B 
cells, dermal dendritic cells, innate lymphoid cells including NK cells, and macrophages 
(30,31). 
Figure 1. Skin basement membrane (BM) has three layers: lamina lucida,
lamina densa, and sublamina densa. In lamina lucida, hemidesmosomes
attach basal keratinocytes to BM. Lamina densa contains mainly type IV
collagen (23) but also laminins, as well as nidogen and perlecan.
Sublamina densa connects lamina densa to underlying papillary dermis. 
Sublamina densa connects to anchoring plaques by anchoring fibrils and
microfibrils of type VII collagen and heparan sulfate proteoglycan. 
 
This figure is reproduced under the Creative Commons Attribution 





Connective tissue cells – Fibroblasts 
Fibroblasts are the main population of cells in dermis forming a poorly-defined group 
of cells. Fibroblasts are any stromal cells that express no markers for more specific 
mesenchymal lineage leading to heterogeneous and dynamic cell lineages that vary across
tissue types. Different layers of human dermis exhibit different subpopulations of 
fibroblasts with unique properties (32). In dermis, fibroblasts express different quantities 
and ratios of collagen type I and type III mRNAs depending on their resident depth (32). 
Papillary dermis has more collagen type III than reticular dermis (33). Adult intact skin 
contains collagen I to collagen III in a ratio approximately 4:1 (34). Fibroblasts in the 
deeper dermis produce less collagenase enzyme (matrix metalloproteinase-1, MMP-1) 
mRNA than their “peers” in a more superficial location (35). Papillary and reticular 
fibroblasts also show a different profile in ECM synthesis, and growth factor and cytokine 
secretion. These different fibroblast populations possess distinct abilities to promote 
keratinocyte growth, migration, and differentiation, and in influencing both synthesis and 
remodeling of ECM in the dermis.  
Extracellular matrix (ECM) of dermis – an active scaffold  
ECM has been estimated to contain approximately 300 core proteins (36). Some 
selected proteins important in wound healing are addressed in this chapter. 
ECM is the non-cellular component of tissue providing support for cells. It not only 
anchors cells, but also modifies cellular properties and regulates cell behaviour, and in 
turn cells build and (re)model ECM. There is a constant interaction between cells and 
ECM. ECM controls the majority of cell functions: cell proliferation, migration, 
differentiation, growth, survival and particularly the stemness of stem cells, cell adhesion 
and cell-cell communication contraction, transmission of forces into the cells, changes in 
shape, protein synthesis and expression of specific genes, degradation of proteins, and 
apoptosis (27,32,37,38). Skin ECM forms a dynamic interlocking network with a variety 
of macromolecules like proteolytic enzymes and their tissue inhibitors, growth factors and 
cytokines (39), serving as their reservoir and regulating their bioavailability. ECM also 
functions as physical barrier, as a track for cellular movement, and a binding site for cells.  
The (bio)chemical and physical properties of ECM influence cellular behavior like cell 
migration, growth, and differentiation (40). The biochemical characteristics of ECM 
enable cells to sense and to interact with their microenvironment by different signal 
transducing pathways (36). Cells sense chemical signals like growth factors and different 
metabolic precursors. Signaling molecules bind to adhesive ECM proteins such as 
fibronectin, laminin, and collagens. These proteins in turn bind to cell surface integrins, 
which function as links between cells and ECM (36). Physical features of ECM like 
rigidity, elasticity, density, porosity, spatial arrangement, orientation, insolubility, and 
mechanical tension are sensed by the cells through integrins. Integrins are connected to 
cytoskeletal actin and mediate mechanical cues inside the cells (27). These interactions 
may affect migration, proliferation, differentiation, apoptosis, and stem-cell fate. 
Contraction of ECM may result in tensile stretch in cytoskeleton and nucleus. 
Compression of ECM may alter local ion concentrations thereby activating ion channels 
(40,41). The increased rigidity of ECM may increase proliferation and contractility. The 
stiffness of ECM also regulates the differentiation of mesenchymal stem cells: rigid ECM 
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leads to the osteogenic path whereas soft ECM favors the neurogenic path (36). The ECM 
laxity or rigidity is linked to fibroblast apoptosis signaling and MMP activity. Matrix 
stiffness is known to induce myofibroblast differentiation (32,42-44).
The main components of dermal ECM consist of collagens, elastin, proteoglycans, and 
glycoproteins as cell adhesion molecules (32,36). The different macromolecules in the 
dermis occupy distinct tasks: collagens (and laminins in BM) serve as structural proteins; 
elastins and fibronectins provide flexibility; proteoglycans and hyaluronan maintain the 
three-dimensional structure and bind growth factors. On the other hand glycoproteins on 
the cell surface like integrins regulate cell adhesion and mediate signaling between cells 
and the ECM (39).  
Fiber-forming structural proteins create a three-dimensional structure. The most 
abundant fiber-forming structural proteins include collagens, fibrin, fibronectin, 
vitronectin, elastin, and fibrillin. Collagens provide integrity, rigidity, and elasticity to the 
tissue (45). Fibrin, fibronectin, and vitronectin are compounds of a healing wound. 
Fibronectin has an important role in guiding inflammatory cells and fibroblasts to the 
wound site (46). Elastin endows resilience to skin (47). 
Non-fiber-forming structural proteins create a charged, dynamic, and osmotically 
active microenvironment. Proteoglycans and glycosaminoglycans (GAGs) fill the most 
interstitial space in the dermis (48). Proteoglycans are glycosylated proteins that provide 
mechanical support. They are able to regulate cell proliferation, migration, protein 
synthesis and degradation, and apoptosis (37). They consist of a core protein combined 
with GAG chain or chains. Together with other matrix proteins like collagens, 
proteoglycans (such as decorin, biglycan, fibromodulin, and versican) form a 
supramolecular structure to increase the stiffness of the tissue. Sulfated GAGs are often 
part of proteoglycans. The GAG chains are highly negatively charged, they enable space-
filling, lubrication, hydration, and buffering functions of proteoglycans, and they 
distribute forces within the tissue (36). They maintain the mechanical strength of the tissue 
(49) and serve as storage for growth factors and other proteins. GAGs may function as a 
physical and biochemical barrier, creating a special microenvironment restricting the free 
movement of proteins (50). This specific microenvironment may be crucial for creating 
stem cell niches and to protect the stem cells from exposure to growth factors and receptor 
binding in order to maintain the stem cells in an undifferentiated state. The GAGs assist in 
interaction with other ECM components. 
Four major classes of GAGs have been identified: heparan sulfate, chondroitin 
sulfate/dermatan sulfate, keratan sulfate, and hyaluronan, also called hyaluronic acid. 
Dermatan sulfate is also known as chondroitin sulfate B, and chondroitin-6-sulfate is 
known as chondroitin sulfate C (51). Dermatan sulfates take part in cell signaling through 
interactions with collagen and transforming growth factor-β (TGF-β) (52). 
Proteoglycan decorin (DCN) regulates collagen fibril and fiber bundle organization 
and the tensile strength of dermis (39). It binds to specific locations on the surface of type 
I collagen fibrils (27) and it interacts with fibronectin, thrombospondin, epidermal growth 
factor receptor (EGFR), and TGF-β (53). It regulates the production of EMC molecules 
such as fibronectin and thrombospondin-1. In addition to blocking the action of TGF-β by 
forming an inactive complex DCN exerts anti-fibrotic effects by inhibiting collagen I 
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maturation, and stimulating collagenases (53). DCN also regulates inflammation by 
recruiting mononuclear cells to the site of injury by inducing MCP-1 (54). 
2.1.4 SUBCUTIS OR HYPODERMIS
Subcutis is a layer between dermis and fascia. This mainly adipose tissue functions as 
a cushion against physical pressure from outside. It also retains moisture and generates 
heat, provides thermal insulation and takes part in adaptive immunity (55). Between 
adipose cells, connective tissue fiber bundles reach from dermis to fascia and periost. 
Abundant mesenchymal stem cells also reside in adipose tissue and subcutis serves as 
reservoir for adipokines, which can exert pro- or anti-inflammatory functions (56).  
A distinct adipose tissue type has recently been identified: dermal white adipose tissue 
(dWAT), a layer that comprises adipocytes in the reticular dermis, located primarily 
perifollicular, and superior hypodermis. Its functions differ from other adipose tissue; 
dWAT takes part in hair cycling, thermogenesis, wound healing, scarring and fibrosis, and 
immune defense producing cathelicidins and communicating directly with various types of 
cutaneous immune cells. (57) 
2.1.5 SKIN HOMEOSTASIS AND MAINTENANCE BY ECM AND DERMAL 
FIBROBLASTS 
ECM produced by dermal fibroblasts contributes to stem cell niche homeostasis by 
influencing local tissue architecture and the signaling microenvironment.  
The epidermal stratification process depends on dermal fibroblasts. Complex 
interactions between epidermal keratinocytes and dermal fibroblasts are required in order 
for stratification to proceed properly. For example, IL-1α from epidermal keratinocytes 
induces dermal fibroblasts to produce of keratinocyte growth factor (KGF) and 
granulocyte macrophage colony-stimulating factor (GM-CSF) that in turn stimulate 
keratinocyte proliferation and differentiation (58,59).
2.2 CELL STRUCTURE AND FUNCTION 
This chapter is provided to give a very brief overview of structure and function of 
keratinocytes and fibroblasts focusing on cell cycle, gene expression and cell signaling.  
In general cells are surrounded by cell membrane, a barrier controlling the entry and 
exit of substances. The inside of cells contains cytoplasm, a nucleus with DNA, and cell 
organelles like Golgi, mitochondria, endoplasmic reticulum with or without ribosomes, 
and cytoskeleton.  
Cytoskeleton includes microfilaments, microtubules, and intermediate filaments, and it 
is responsible for mechanical support, anchoring organelles, and cell movement. It is also 
involved in transportation macromolecules within the cell.  
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2.2.1 CELL CYCLE  
The aim of the cell cycle is to duplicate, divide, and distribute chromosomal DNA into 
two genetically identical daughter cells. The cell cycle has two major phases, synthesis (S) 
and mitosis (M); and two minor or gap phases between the major phases, G1 between M 
phase and S phase, and G2 between S 
phase and M phase (60). See figure 2.  
If the conditions are unfavourable, 
the cell either lengthens G1 phase or 
may enter a resting phase, G0. In 
favourable conditions, the G0 or the 
beginning of G1 phase proceeds 
towards the end of G1 phase to a 
commitment point, after which the 
replication of DNA is carried on even 
if the cell division stimulating 
extracellular signals are removed. 
During G2 phase, cellular growth and 
protein synthesis takes place. The 
sequential phases from G1 to S 
followed by G2 together are called 
interphase (61).  
A detailed description of gene 
replication is reviewed elsewhere 
(62,63). 
2.2.2 GENE EXPRESSION 
Made up of DNA, genes carry the instructions for proteins to be synthesized. When a gene 
is activated (e.g. through a signaling pathway) its instructions are decoded via transcription 
(of the nucleotide sequence), where the information is copied to create a complementary 
messenger RNA (mRNA). This copy is then translated to sequences of amino acids by 
ribosomes with the help of transfer RNAs (tRNAs) to build a protein or a protein precursor. 
See figure 3. 
Transcription 
In gene transcription, the information of a gene is copied from the gene’s DNA 
sequence by RNA polymerase to create a complementary RNA strand, a transcript. 
Transcription is regulated by transcription factors and coactivators and takes place in the 
nucleus. The next step, translation of the code to amino acid sequence, occurs by 
ribosomes in cytoplasm or across endoplasmic reticulum. 
RNA polymerase enzyme “manufactures” the new messenger RNA molecule by 
attaching to DNA in a specific promoter region with the help of transcription factor. The 
transcription factor binds to DNA at a specific target sequence and thereby either assists or 
inhibits the binding of RNA polymerase. 
Figure 2. Phases of cell cycle.  
Reproduced here under the Creative Commons Attribution 
License CC BY-NC-SA 2.0 UK from 
https://www2.le.ac.uk/projects/vgec/highereducation/topics/cellc
ycle-mitosis-meiosis. Copyright 2019 Clinical Tools, Inc. 
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Gene promoters are regions of DNA, typically located upstream of the gene, in near 
proximity to the target gene that assists the RNA polymerase to attach to DNA and to 
begin the transcription/copying of the DNA.  
Transcription factors are proteins that regulate transcription. They function as 
activators that boost transcription of a 
gene whereas repressors decrease the 
transcription. Transcription factors bind 
to nearby DNA. These binding sites are 
called enhancers and silencers which can 
either turn a gene on or off. 
In eukaryotic cells, the manufactured 
“primary transcript” mRNA needs further 
processing before leaving the nucleus. 
These post-transcriptional modifications 
of mRNA protect the transcript and assist 
in leaving the nucleus and for mRNA to 
become mature mRNA called an exon. 
After transcription, the transcript may 
also undergo an alternative splicing 
resulting in different (mRNAs and) 
proteins from the same RNA transcript. 
MicroRNAs are small 
posttranscriptional regulator-RNAs that 
can cause silencing of the gene by 
degrading mRNA or by blocking mRNA 
translation.(64). 
Translation 
Translation of the mature mRNA transcript takes place in a ribosome. (65,66).  
After translation, the produced amino acid sequence form either a functional protein or 
they form a precursor of protein, an inactive pro-protein that requires further processing 
before becoming fully active. In order to become fully active, the protein may undergo 
proteolysis by proteasomes or post-translational modification and protein folding in the 
endoplasmic reticulum. Endoplasmic reticulum is responsible for the quality control of 
synthesized proteins. Unfolded or misfolded proteins are either degraded or they 
accumulate in the cell leading to cell dysfunction. (64). Depending on the severity of the 
dysfunction, this leads either to reduced general protein synthesis or to the apoptosis of the 
cell (21). 
 
2.2.3 CELL SIGNALING 
Cell signaling refers to processes that take part in endocrine, paracrine, juxtacrine, 
autocrine, and intracrine cellular communication and affect cellular behavior (67). Cells 
communicate with each other and their microenvironment by responding to and sending 
Figure 3. Gene expression.– from DNA to protein 
Transcription in nucleus. DNA strand is copied into a 
messenger RNA. 
Translation in cytoplasm. Messenger RNA is translated by 
ribosome. The code of mRNA is translated to sequences of 
amino acids forming a protein or a precursor of a protein. 
Figure reproduced here with permission from the copyright 
holder from 
https://www.nature.com/scitable/topicpage/gene-expression-
14121669. Copyright 2010 Nature Education. 
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chemical messages, although signals received may also be physical: mechanical, osmotic, 
thermal, electrical or light-related (68). Extracellular signaling involves the triggering 
physical parameter or the chemical signaling molecule, the mediator of the message. 
Intracellular signaling includes receptor activation that leads to a series of intracellular 
biochemical reactions or conformational changes called a signaling pathway. One 
signaling pathway may interact with another forming a network. Signaling pathways can 
be regulated by positive or negative feedback. Cellular responses to signals may include: 
increasing transcription of a certain gene; a metabolic response like enzyme activity; or 
cell growth, proliferation, migration, differentiation, or apoptosis. (68).  
The effect of the signal may induce fast, slow, or even permanent changes in cell 
behaviour. Short-term cellular changes include changes in shape, secretion, contraction or 
relaxation, migration, and changes in metabolism. Long-term cellular changes may 
include gene expression, proliferation, differentiation, cell survival, and apoptosis. Based 
on mathematical modelling, it has been suggested that short-term signaling may determine 
long-term cell fate (69). More detailed information regarding the concept of cell signaling 
was reviewed recently (70).
Extracellular signaling 
Cytokines and growth factors are signaling molecules that mediate the signals from 
ECM or from another cell into the target cell. Cytokines like interleukins, lymphokines, 
interferons, chemokines, and TNF-α, are small proteins that pre-dominantly have an effect 
on immune cells (71) whereas growth factors are heterogeneous secreted molecules that 
mainly regulate growth and differentiation of various cell types (72). Some cytokines and 
growth factors important in wound healing are presented in Table I.  
ECM molecules as signaling molecules 
ECM molecules interact with cell surface receptors that forward signals from the cell 
membrane to molecules in the cytoplasm. ECM-cell interactions promote cell adhesion, 
migration, growth, differentiation, and apoptosis, and affect activities of growth factors 
and cytokines. The molecules of the ECM are able to bind either to growth factors or 
directly to their receptors to mediate signaling: fibronectin binds fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor 
(PDGF). Tenascin-C and laminin-5 interact with epidermal growth factor receptor (EGFR) 
promoting cell proliferation. In contrast, decorin-induced activation of EGFR inhibits 
mitogenic signaling in fibroblasts and endothelial cells. Decorin takes part in multiple 
signaling pathways by binding to and activating growth factor receptors like insulin-like
growth factor 1 receptor (IGF1R) and TGF-β. Decorin interacts with macrophages and 
simultaneously activates transiently mitogen-activated protein kinase (MAPK) and NF-κB
signal pathways and enhances the release of inflammatory factors like TNF-α and IL-10. 
Growth factors regulate ECM structure in co-operation with proteases: growth factors 
initiate deposition of ECM components, while proteases enable their degradation, ensuring 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Receptor proteins on cell membranes bind to signaling molecules, which leads to 
responses such as a conformational change of the receptor, which in turn transmits the 
signal to commence the signaling pathway. See Figure 4. Direct cell-cell contact can lead 
to stable interactions. Signal transduction into the cell may occur also through binding of 
the messenger to primary cilia. Primary cilia a cell organelle containing a certain subset of 
receptors and other proteins involved in signaling, detecting, and transmitting signals from 
the surrounding of the cell into the cell (74). Primary cilia are found on the surface of 
many growth-arrested or differentiated eukaryotic cells. See chapter Primary cilia for 
further details.  
Cell surface receptors  
Most receptor tyrosine kinases (RTKs) take part in regulating complex functions like 
proliferation and differentiation (75).
Integrins are transmembrane receptors, proteins that cells use to respond to and attach 
to the ECM. They function as “dual receptors.” They transduce signals both from the 
external environment into the cell, and from inside to out, functioning as links between the 
ECM and the cytoskeleton of the cell. Integrins are coupled to intracellular cascades that 
can affect cell proliferation, differentiation, polarity, contractility, and gene expression 
(36). They are able to have crosstalk with receptor tyrosine kinases like EGFR (76). Some 
ECM molecules function as ligands to integrins leading to activation of the MAPK 
pathway.  
Intracellular signaling  
Altogether 177 different signaling pathways have been identified (Panther 
classification system, Geneontology, Panther 14.1). This chapter focuses on the most 
important signaling pathways related to wound healing. 
In wound healing many of the processes, such as cell proliferation, motility, and 
survival are regulated by multiple pathways. Epidermal cell differentiation, barrier 
function, and apoptosis are also affected by various signaling pathways. Several key 
signaling pathways (77) participate in mammalian cutaneous wound healing, such as 
Wnt/β-catenin, TGF-β, Hedgehog, and Notch pathways. The NF-κB signaling pathway 
has an important role in inflammation. 
The Wnt/β-catenin pathway is involved in reconstruction of dermis by affecting the 
numbers of fibroblasts, cellularity, and matrix production. In epidermis it may sometimes 
be involved in regeneration of hair follicles in large wounds. Several components of ECM  
act through the Wnt -pathway to regulate hair epidermal stem cell activity (78). TGF-β1 is 
one of the key regulators produced by keratinocytes. The TGF-β1 signaling pathway takes 
part in reconstitution of dermis by affecting fibroblast proliferation, matrix synthesis, 
fibroblast differentiation into myofibroblasts, and wound contraction. In epidermis, TGF-
β1 has an inhibitory role of re-epithelialization. 
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Hedgehog pathway has been associated with accelerated wound healing, and Sonic 
hedgehog (Shh) participates in hair follicle regeneration. It has also been suggested to 
promote fibroblast proliferation and angiogenesis (77). 
Notch signaling affects macrophage behaviour and angiogenesis. During skin 
development it affects epidermal differentiation and participates in asymmetric cell 
division during epidermal stratification (79). 
The NF-κB Signaling Pathway has been regarded to have a critical role in 
inflammation, the innate and adaptive immune response, and stress. Dysregulated 
signaling is seen to occur in inflammatory and autoimmune diseases (18,80).
The MAPK signaling pathway has been shown to have critical role in epidermal 
differentiation as well as in skin barrier function. The MAPK signaling pathway 
components can integrate and mediate various signals involved in keratinocyte 
differentiation. 
 The ERK1/2 signaling pathway has been shown to control keratinocyte 
differentiation; low ERK1/2 activity could induce keratinocyte differentiation and 
apoptosis (81). Under normal circumstances the signals for proliferation of keratinocytes 
are mediated through EGFR following the MAPK pathway. This mitogenic activity is 
limited to basal keratinocytes (76). Signaling pathways known to be crucial for epidermal 
stem cell homeostasis and skin morphogenesis include Wnt, TGF-β/BMP, Notch, 
Hedgehog, and FGF. Wnt/β-catenin signaling is well recognized to play a role in 
controlling epidermal stem cell maintenance and fate decision. It participates in multiple 
processes in the skin, including cell-matrix interactions within the niche and outside (82). 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cilia are microtubule-based specialized cell organelles that interact with the 
extracellular environment and/or generate motion. Cilia are able to sense chemical, 
mechanical, and osmotic stimuli, as well as pH, oxygen concentration, and light 
(photoreceptors). They transduce chemical and mechanical signals into the cells 
controlling for example cell polarity, differentiation, and proliferation (83). Three major 
types of cilia have been identified: primary cilia, motile cilia, and nodal cilia (84). Primary 
and motile cilia share a common architecture consisting of an axoneme and a nine doublet-
ring of microtubules as a central structure, as well as a ciliary membrane. Primary and 
motile cilia can be distinguished by the absence of a central pair of microtubules and a 
lack of dynein arms in primary cilia (84). See Figure 5. Nodal cilia share characteristics of 
both motile and primary cilia. Nodal cilia have a 9+0 axoneme, like primary cilia, but 
contain dynein arms like motile cilia.  
Primary cilia 
Primary, also called sensory or non-motile, cilia are present on most vertebrate cells. 
They were found in fibroblasts in 1962 by Sorokin, and in keratinocytes 1963 by Wilson 
and McWhorter (85). They appear as cellular antennae-like protrusions of cell membrane 
that receive and transduce extracellular chemical or mechanical signals into the cell (86). 
Primary cilia are cell organelles that are assembled in cells during normal cell cycle 
progression in G1–S phases. They are assembled by centrioles of the mother centrosomes 
that have relocated from the nuclear membrane to the plasma membrane. In some cells, 
the disassembly of primary cilia is required by the end of mitosis to prevent a G1/S arrest, 
whereas in certain cell types, the ciliary membrane may persist through mitosis (87). The 
centrosomes can be seen as intracellular hubs, whereas primary cilia function as receivers 
of extracellular signals transmitting them into the cell. It has been suggested that there is a 
link between proliferation and ciliogenesis, but not all proliferating cells form primary 
cilia. Cilia take part in and act as key coordinators of signaling pathways during 
Figure 5. Typical structures and function of motile and non-motile cilia. 
Reproduced from Nat Rev Mol Cell Biol. 2017 Sep; 18(9): 533–547. Genes and molecular pathways underpinning 
ciliopathies, Jeremy F. Reiter with the permission of Springer Nature. 
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development and in maintaining tissue homeostasis (88). A single primary cilium can 
respond to several different kinds of signals and the same cilium may possess different 
receptors and different channels (88). Ciliary signaling coordinates cell migration, 
differentiation, transcription, cell division, cell polarity, and apoptosis (89). Misregulation 
or delay in primary cilia loss leads to defects in cell cycle progression, which cause 
aberrant development or imbalanced homeostasis seen in ciliopathies and many cancers 
(83). Some specialized primary cilia act as sensors for light, temperature, osmolality and 
gravity (90).  
Various signaling pathways have been linked to the cilium, including Hedgehog, Wnt, 
Notch, Hippo, GPCR, PDGF (and other RTKs including FGFR, EGFR and IGFR), 
mTOR, and TGF-β (91) as well as NF-kappa B signaling and TGFβ/BMP signaling 
pathways (92). 
Primary cilia and cell–cell junctions, including the adherens and tight junctions share 
several similar features: they are markers of cell polarity in epithelia; sites of 
mechanosensation; transducers of signals; and are regulated by the actin cytoskeleton (83).  
During development, the composition of ciliary signal systems may change as part of 
the dynamic process that controls cell differentiation, allocating different signal systems to 
different cell types to determine cell fate and function.  
In keratinocytes, the cilium is a typical feature of 
post-mitotic and differentiated cells which have 
exited the cell cycle (91). Figure 6. shows a cross-
section of keratinocyte with cilia. 
The fibroblast primary cilium, similarly to GPS, 
may coordinate cellular directional migration and 
PDGFRα-mediated chemotaxis. Primary cilia may 
also directly interact with extracellular matrix 
(ECM) proteins as the cell moves, transmitting 
mechanical information from the outside milieu to 
the cell. Recent work has further shown that stem 
cells possess primary cilia with signal transduction 
components that control maintenance of stem cell 
pluripotentiality and regulate early differentiation 
and proliferation.(93) Signaling through PDGFRs 
has been associated with resorption of cilia, an 
important step in cell cycle progression to permit the 
centrioles to participate in mitosis (91). 
Motile cilia 
Motile cilia are higher specialized organelles than primary cilia. They appear in 
differentiated specialized cells and generate bending waves to take part in cell motility or 
in transportation of fluids over the cell surface (94-96). Motile cilia differ from sensory 
primary cilia by the presence of motor proteins required to move fluid in the brain, 
respiratory, and reproductive tracts (97). An increasing amount of evidence suggests that 
Figure 6. Keratinocytes. Arrows are
pointing at cilia. Reproduced from Journal of
Ultrastructure Research, 87, 212-220, (1984)
Rolf Elofsson, The Ciliated Human
Keratinocyte, with permission from Elsevier.
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motile cilia can mediate sensory functions, as well as exhibit mechanoreceptive and 
chemoreceptive properties (98). 
Dyneins 
Dyneins are a family of force generating motor proteins associated with microtubules. 
Dyneins are categorized into two main classes: axonemal and cytoplasmic. Motile primary 
cilia have also been recently discovered, like vertebrate nodal cilia that promote left-right 
asymmetry during development (99). Axonemal dyneins are expressed in cilia. Axonemal 
dyneins within motile axonemes cause sliding or bending along the axoneme resulting 
oscillation (100); outer-arm dyneins seem to be responsible for increase the frequency of 
axonemal beating, whereas inner-arm dyneins have distinct roles in shaping the ciliary 
waveform (95). 
Cytoplasmic dyneins transport and position protein complexes and cell organelles 
inside the cells (101). Cytoplasmic dyneins may also translocate membrane-spanning 
proteins and signaling complexes in the plane of the lipid bilayer, for instance within the 
nuclear envelope (100). Cytoplasmic and axonemal dyneins show similarities in heavy 
chains across different species. Dyneins vary in their properties especially in velocities in 
translocation of microtubule (95). According to their location on the microtubule doublet, 
the axonemal dyneins are called either inner or outer arm dyneins. The inner-arm dyneins 
are further divided into two functionally different subgroups: two-headed inner-arm 
dyneins (DNAH10 belongs to this group) and one-headed inner-arm dyneins. Dynein arms 
of cilia are preassembled in the cytoplasm before transporting to into cilia (94). Dyneins 
“walk” towards the minus ends of microtubules.
Ciliopathies 
Ciliopathies vary from absence of cilia in specific tissue to malfunction/dysfunction of 
ciliary motion like reduction or lack/loss of motility. Primary ciliary dyskinesias are 
ciliopathies with known dysfunction of motile cilia caused by genetic recessive disorders. 
Out of these, the most well-known are dysfunction in respiratory and reproductive 
cilia/flagella and lateral asymmetry as situs inversus (nodal cilia disorder). 
2.3 WOUND HEALING  
Wound healing is a complex process involving timely overlapping interaction between 
different types of cells and interplay between the cells and the ECM of the wound bed in a 
designated sequence. In man, wound healing is not a true regeneration of tissue after early 
gestation, 0–24 weeks (102), instead it results in an inferior quality of connective tissue, a 
scar.  
During cutaneous wound healing, the barrier function and mechanical properties of 
skin are restored by the actions of numerous types of cells which undergo proliferation, 
migration, differentiation, and apoptosis to rebuild the skin.  
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2.3.1 WOUND HEALING PHASES 
Wound healing and scar formation involve epidermal, dermal, and subcutaneous 
mesenchymal cells, endothelial cells, and cells of the immune system and neurons. Wound 
healing is traditionally divided into four overlapping phases: hemostasis; inflammation; 
proliferation; and re-modeling. 
Hemostasis  
To reduce bleeding, blood vessels contract and a coagulation cascade is activated to 
produce fibrin net, and together with adhering and aggregating thrombocytes to form a 
clot. Hemostasis is achieved from minutes to hours after injury. Platelets and the cells 
from the fibrin clot and surrounding wound bed release pro-inflammatory cytokines, and 
growth factors such as TGF-β, PDGF, FGF, and EGF, attracting inflammatory cells as 
well as proliferating cells to the wound site.(103). 
Upon wounding and breach of the epidermal barrier, keratinocytes also secrete pro-
inflammatory cytokines IL-1, TNF -α and growth factor EGF (104).  
Inflammation 
Inflammation phase can be separated into two distinct phases: early and late 
inflammation. Early inflammation serves to defend against microbial invasion and 
infection and late inflammation is a transition phase towards tissue repair.  
Inflammatory cells migrate into the wound area. Leukocytes infiltrate the wound 
sequentially: neutrophils, macrophages, and lymphocytes (105). Neutrophils are the first 
leukocytes to arrive at the injured wound site within a few minutes, followed by 
monocytes/macrophages and lymphocytes (71). Mast cells release histamine and cytokines 
promoting the inflammatory phase, stimulating vasodilatation and increasing vascular 
permeability. Neutrophils combat invading microbes by secreting reactive oxygen species, 
antimicrobial peptides, and antimicrobial proteases (106). Cytokines released by 
neutrophils during apoptosis are chemotactic for monocytes. Monocytes converting into 
macrophages start to arrive 5 to 6 h after injury. Macrophages decrease the numbers of 
bacteria, secrete various cytokines and growth factors and phagocytose apoptotic 
neutrophils. Macrophages initiate granulation tissue formation (107). Other inflammatory 
cells also take part in initiating the proliferation phase by secreting growth factors and 
cytokines. 
Classically activated M1 macrophages possess pro-inflammatory properties whereas 
M2, alternatively activated macrophages, are anti-inflammatory cells. Towards the 
transition from the inflammation to proliferation phase, macrophages change their 
phenotype from M1 to M2 leading to decrease of inflammatory cytokines and increase of 
anti-inflammatory cytokines (108). The removal of M1 macrophages at early stage has 
been shown to reduce granulation tissue formation, to impair epithelialization, and to 
reduce scar formation (106). M2 macrophages are a prominent source of cytokines and 
growth factors that promote matrix deposition like TGF-β, PDGF, IGF1, TNF-α, and 
angiogenesis by releasing angiogenic factors including FGF-2, VEGF, placental growth 
factor and by releasing degrading enzymes (106). Cytokines and growth factors produced 
by macrophages activate keratinocytes, fibroblasts, and endothelial cells (108). During 
inflammation, macrophages also secrete chemokines that attract T cells to the wound site. 
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Epidermal and dermal T-cells produce pro-inflammatory cytokines and epithelial growth 
factors (109,110). Tissue-resident γδT cells likely regulate keratinocyte proliferation and 
differentiation by secreting growth factors (106). T-cell receptor (TCR)-specific activation 
of γδT cells accelerates the rate of early wound closure. Th2 cells and regulatory T cells 
(Tregs) also contribute to matrix formation by secreting TGF-β1, IL-4, -5, -13, and -21, 
which enhance anti-inflammatory macrophage polarization and suppress other 
inflammatory cell types. The resolution of inflammation is largely dependent upon 
macrophages, Tregs, and Th2 cells. Tregs seem to control Th2 responses (111). αβ T
lymphocytes in the skin are long-lived resident memory T cells (TRM). Most are derived 
from antigen-specific effector T cells, which previously infiltrated the tissue as a result of 
an infection. TRM promote recruitment of other memory T cells from the periphery to 
sites of infection (112). Antigen-presenting cells with memory T cells are found around 
the hair follicles.  
Proliferation Phase 
In the proliferation phase, the wound bed is filled with new extracellular matrix 
produced mainly by fibroblasts and differentiated myofibroblasts with simultaneous 
(re)building of the vascular network by angiogenesis of endothelial cells and covering the 
wound with migrating and proliferating keratinocytes by re-epithelialization. 
Concomitantly, the myofibroblasts contract the wound to reduce its size to hasten wound 
closure. 
Fibroplasia 
The synthesis of new ECM into the wound bed driven by fibroblasts is called 
fibroplasia. The formation of granulation tissue formation begins 2–4 days after injury. It 
consists of blood clot, fibroblasts and their progenitors, as well as endothelial cells and 
inflammatory cells. Myofibroblasts in granulation tissue have similar functions as 
fibroblasts in terms of synthesizing ECM and contractile properties (34). TGF-β1
enhances granulation tissue formation by mediating the increase of fibronectin, the 
fibronectin receptor, and collagen and protease inhibitors (107). It also promotes ECM 
synthesis by stimulating mesenchymal cells to differentiate into myofibroblasts.  
Angiogenesis and lymphangiogenesis 
The formation of new blood vessels is critical to restore oxygen and nutrition supply to 
the wound site and to support the new building tissue. Angiogenesis takes place in 
response to pro-angiogenic factors like VEGF, FGF, angiogenin, angiotropin, and 
angiopoietin-1 released by wound site macrophages and keratinocytes (113). Angiogenesis 
is also stimulated by lactic acid, plasminogen activator, collagenases, and low oxygen 
tension (114). Beside a sufficient vascularization, lymphatic vessel formation is essential 
to re-establish skin function. Dermal lymphatic vessels are involved in the regulation of 
tissue fluid homeostasis and immune cell trafficking. Adipose tissue-derived stem cells 
have shown potential to support lymphangiogenesis. 
Re-epithelialization 
Upon wounding and release of inflammatory cytokines, basal keratinocytes become 
activated and migrate into the wound (115). The re-epithelialization of a wound requires 
coordinated interactions among inflammatory cells, keratinocytes, fibroblasts, vascular 
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endothelial cells, and immune cells, as well as the local microenvironment. Epithelial stem 
cells contribute to the re-epithelialization by differentiating into epithelial cells. The first 
signal from the injury is the release of IL-1 which activates endothelial cells and 
fibroblasts and attracts lymphocytes to the wound site (21). Keratinocytes and fibroblasts 
take part in reconstructing BM by both producing BM components. BM has an important 
function by regulating keratinocyte growth and terminal differentiation (116).
Remodeling phase 
During the remodelling phase, the newly generated tissue is organized. It matures and 
simultaneously the cellularity of the scar decreases. The onset of the remodelling phase 
varies in the literature from 7–10 days to 2–3 weeks after injury and it can last for 1 year 
or more. In order for the actual matrix to form, the removal of granulation tissue is 
required. The granulation tissue is replaced by collagen and elastin fibres together with 
proteoglycans and glycoproteins. The formed matrix is then remodelled; TGF-β induces 
synthesis of new collagen, whereas the breakdown of old collagen is induced by PDGF 
(107). Metalloproteinases released by fibroblasts and macrophages degrade collagen type 
III of the granulation tissue and replace it with collagen type I, which is further 
reorganized into parallel fibrils, forming a scar with low cellularity. In keloids the early 
excess of collagen type III is replaced by type I collagen, with a high ratio of type I to type 
III collagen (17:1) compared to normal scars (6:1) (117). 
Apoptosis of myofibroblasts may be promoted by a decrease or absence of mechanical 
tension and by alterations in cell density or protease activity; changes in the pattern of 
secreted growth factors are also thought to contribute to cell death (46). 
Role of stem cell in wound healing 
Stem cells affect all phases of wound healing. Mesenchymal stem cells (MSC) may 
originate from different sources like bone marrow, adipose tissue, dermis and perivascular 
niches (118). MSC enhance wound healing by promoting proliferation of keratinocytes 
and endothelial cells; by decreasing apoptosis; by paracrine signaling; and by 
differentiating into keratinocytes and endothelial cells (108). They are also able to 
differentiate into pericytes and vice versa. MSCs may migrate to the wound site where 
they direct inflammation and antimicrobial activity, promote cell migration, proliferation, 
and differentiation, and recruit other host cells to assist in re-epithelialization and wound 
repair (119). MSCs can reduce inflammation by suppressing T-cells and activating 
macrophages. MSCs regulate macrophages through paracrine signaling supporting the 
transition of inflammatory type M1 macrophages to a type M2 anti-inflammatory 
phenotype which then decreases their expression of inflammatory cytokines and increases 
anti-inflammatory signaling. MSCs decrease TNF-α production and provide anti-scarring 
properties by secreting prostaglandin E2 (PGE2), which in turn induces expression of IL-
10 by T cells and macrophages (120). MCSs also contribute to granulation tissue 
formation (108). 
By differentiatining into keratinocytes MSCs have been shown to enhance the speed of 
re-epithelialization, and increase the number of epidermal ridges, the thickness of the 
regenerated epidermis, and the number of appendage-like structures. In addition MSCs 
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release a variety of growth factors that enhance the proliferation of keratinocytes, 
fibroblasts, and ECs such as IGF-1, EGF, KGF, and other mitogens.(108). 
Adipose-derived stem cells (ASC) have been shown to promote re-epithelialization by 
paracrine activation of keratinocytes by secreting of growth factors like PDGF, FGF-2, 
and TGF-β (108). In a rodent model they also enhanced the granulation tissue formation 
(121). They excert their beneficial influence in wound healing and promote angiogenesis 
by secreting angiogenic factors like HGF, VEGF, GM-CSF, PDGF, SDF-1, FGF-2, TGF-
α, IL-6, and IL-8. Like MSCs ASCs are able to differentiate into keratinocytes as well as 
into fibroblasts and endothelial cells. (122).  
The role and function of dWAT and hair follicle stem cells has been described in the 
chapter of skin structure and function. 
Burn wound healing 
Burn toxins such as free radicals, lipoproteins, lipopolysaccharides, and lipid peroxides 
form as a result of thermal injury to skin. They are liberated during the early stages of 
burns and cause immunosuppression, mitochondrial destruction, energy metabolic 
disorders of cells and increase the permeability of the cell membrane (123). Oxidative 
stress may increase the development of necrosis. Free radicals are also associated with 
formation of pyridinoline cross-links, normally appearing in bone and cartilage, but also 
occurring in hypertrophic scars (46). Heat denatured proteins of the eschar may also result 
in an uncontrolled inflammatory response (123,124).
In large burns exceeding 20 % of total body surface area burn shock takes place in 
addition to local injury. Vasodilatiation and the capillary permeability is increased and 
fluid escape accompanied with proteins leaking from blood vessels into interstitial space 
follows creating edema and on the other hand hypovolemia needing fluid resuscitation 
(125). 
Even though neutrophils have been found in high numbers in burn wounds and for 
prolonged periods of time, their functions were impaired. In burns, mast cells have been 
shown to regulate both the inflammatory and the proliferative phases. Mast cells are 
among the first cells to react in burn injury. They release histamine and cytokines 
promoting the inflammatory phase. Mast cells may enhance tissue remodeling at later 
stage. On the other hand their uncontrolled activity may lead to scar formation.(126). 
Patients experiencing pain in burns secrete neuropeptide substance P increasing the release 
of histamine from mast cells possibly also contributing to formation of hypertrophic scar. 
(46). In burns the immune response is dysregulated. In addition to impairment of 
neutrophils it has been suggested that also T cells contribute deteriorating wound healing. 
The levels of IL-17 and IL-22 cytokines are significantly increased supporting Th17 
responses. The skin-resident γδ T lymphocytes promote Th1, Th17 and regulatory T cell 
responses. (126). In burn wounds expression of the TGFβ-, FGF-, and VEGF families of 
cytokines are increased in keratinocytes which regulate re-epithelialization and 
regeneration of dermal tissue (127). 
The patients fall into hypermetabolic state, chronic inflammation and their immune 
system is compromised leading to increased susceptibility to infection and sepsis and 
delayed re-epithelialization. The deeper and larger the burn is, the greater the level of 
circulating cytokine storm and the more difficult the hypermetabolic response. (125).  
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Regarding hypertrophic scar formation in children’s scald burns, if an accurate 
prediction is made that the burns are expected to heal before 25 days, a better outcome is 
expected with conservative treatment than with skin grafting. In deep burns, the risk of 
pathological scar formation is increased even if the patients are grafted and healed within 
two weeks of injury. (126). 
Early permanent wound closure warrants minimal or no scarring complications, 
whereas delayed treatment often leads to severe hypertrophic scarring which is directly 
proportional to the delay to wound closure. One study of 337 scalded children showed that 
if the wound closure was achieved within 21 days the risk for hypertrophic scar was low, 
and after this time frame a much higher incidence of hypertrophic scarring occurred (126). 
Earlier permanent wound closure is also associated with lower mortality and better 
functional long-term results (109,127,128). The thicker the STSG is, the less contraction 
there will be at the site of application, but the longer it will take to heal the donor site 
(129). Currently, split-thickness autologous skin grafting is the clinical “gold standard” in 
full-thickness injuries treatment (129,130). 
Factors promoting scar formation 
Scarring represents an outcome and “end-product” ECM resulting from wound
healing. Problematic or pathologic scars evolve due to variety of triggering and/or 
predisposing factors. Most of these factors are related to chronic inflammation, 
myofibroblast activation, and/or mechanical stretch of the cells. Other factors may also
contribute to formation of a problematic scar. Morphological characteristics of 
problematic scar are abundant fibroblast proliferation and differentiation into 
myofibroblasts; the excessive production of extracellular matrix (ECM) proteins, 
especially types I and III collagen that accumulate in the extracellular space (39,128); 
decreased apoptosis of myofibroblasts and fibroblasts; and decreased degradation of ECM 
by MMP.  
Fibroblasts of hypertrophic scars resemble deep dermal (reticular) fibroblasts (35). 
Keloid scars do not progress beyond the early stages of wound healing and remain in this 
state for years.  
Role of inflammation 
Pathological scarring can be seen as inflammatory disorders of reticular dermis. 
Chronic inflammation in reticular dermis has been suggested to lead to scarring problems 
such as hypertrophic scars and keloids (129). The sustained cross-talk between 
inflammatory macrophages and myofibroblasts results in prolonged myofibroblast 
activation, wound contraction and excess deposition of ECM especially collagen (34).
ECM influences the pro-fibrotic signals between macrophages and myofibroblasts. In 
keloids and hypertrophic scars the reticular layer contains inflammatory cells, increased 
numbers of fibroblasts, newly formed blood vessels, and collagen. In keloids 
proinflammatory factors such as interleukin (IL)-1α, IL-1β, IL-6, and TNF-α have been 
shown to be upregulated. Systemic factors may also contribute to dermal inflammation. In 
adolescence and during pregnancy, estrogens and androgens intensify inflammation by 
vasodilatation. Systemic inflammation is also likely to be responsible for the tendency of 
patients with extensive burns to develop hypertrophic scars after surgery. In deep and 
large burn wounds, the duration of inflammation is prolonged. The severe burn itself is 
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associated with a cytokine storm that significantly increases the risk of developing keloids 
and hypertrophic scars for at least 1 year. Excess secretion of pro-inflammatory factors 
promotes degradation of both growth factors and ECM. Pro-inflammatory mediators also 
prohibit the conversion of M1 macrophages to M2 macrophages (106). 
Most of the current therapies for scars target reducing inflammation like corticosteroid 
injection/tape/ointment, radiotherapy, cryotherapy, compression therapy, stabilization
therapy, 5-fluorouracil therapy, and surgical methods that reduce skin tension (129). 
Myofibroblast activation and origin of myofibroblasts  
One key factor in the formation of pathologic scars is the numerous myofibroblasts 
producing excess ECM. Myofibroblasts synthesize scar-type connective tissue. Many 
different terms are used for cells converting into myofibroblasts: e.g. fibroblast-to-
myofibroblast transition; myofibroblast (trans)differentiation, activation, or 
transformation; or just fibroblast activation.  
Myofibroblasts may originate from various precursor cells. They can be activated from 
tissue resident fibroblasts, from circulating fibrocytes, from pericytes, and they may be 
formed by transdifferentiation from epithelial-mesenchymal (EMT) or endothelio-
mesenchymal transition (34). Dermal adipocytes may also undergo adipocyte-
myofibroblast transition (AMT) (130). In addition to fibroblasts, other fibroblast-like cells 
take part in wound healing. Some fibroblasts or fibroblast-like cells may originate from 
bone marrow-derived mesenchymal stem cells, whereas fibrocytes originating from 
mononuclear cells also have similarities with mesenchymal cells. During wound healing 
even up to 30% of cells with a similar phenotype to fibroblast and myofibroblast are 
suggested to originate from circulating hematopoietic fibrocytes. (131,132) 
Myofibroblasts may form from cells of mesenchymal origin like adipocytes and pericytes 
by de-differentiation to fibroblasts (32). Decreased apoptosis also contributes to the 
number of wound site myofibroblasts (133). 
TGF-β1 is the most well-known inducer of myofibroblast differentiation. It seems to 
necessitate the presence of a splice variant of fibronectin EDA. TGF-β1 is in the ECM in a 
latent form that needs to be activated by degrading enzymes. Profibrotic effects of TGF-β
are mediated via Smad-proteins and altered expression of the connective tissue growth 
factor (CTGF) gene. CTGF is a well characterized downstream target of TGF-β that 
promotes fibrotic response and ECM production (133). TGF-β1 signals may also be 
mediated via Smad-independent pathways, including p38 MAPK, ERK, JNK, and c-Abl.
Fibrin degradation product FnE potentiates the myofibroblast activation and 
recruitment induced by TGF-β (134). Proinflammatory factors promote degradation of 
growth factors and ECM and thus also activating latent TGF-β1. Another factor known to 
induce myofibroblast differentiation is mechanotransduction, stretching the cell and 
stiffness of the matrix. The signaling cascade involves integrin/FAK/Src via ERK and 
MAPK pathways. Matrix stiffness is increased with cross-linking by lysyl oxidase-like 2 
(LOXL2) enzymes. Inhibition of these enzymes results in less mechanical stress. Many 
integrins (such as α3β1, α11β1, αvβ3, α4β7, and β1 integrin) contribute to fibrosis and 
myofibroblast differentiation through various pathways (135). Periostin is shown to 
contribute to myofibroblast activation. Hyaluronic acid (HA) and its receptor CD-44 are 
involved in myofibroblastic activation; high molecular weight HA inhibits fibrotic 
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pathways, but low molecular weight HA appears to induce them. Collagen III deficiency 
promotes myofibroblast activation and wound contraction (136). 
Fibroblasts are the main executors of scar formation and driving myofibroblast 
differentiation in concert with macrophages, other inflammatory cells, epithelial cells, 
cytokines, and growth factors (137). 
Role of re-epithelialization and basement membrane 
A burn wound that heals in less than 10 days has a 4% risk of developing into a 
hypertrophic scar (138,139). In case re-epithelialization is delayed up to 2 to 3 weeks, one 
third of the wounds develop hypertrophic scarring. If re-epithelialization is prolonged up 
to three weeks or more, the risk for hypertrophic scarring increases to 78% (140).  
Scar tissue derived keratinocytes differ from normal keratinocytes, the thickness of 
epidermis is increased, and the basement membrane may be absent or aberrant in scar 
tissue (141). In hypertrophic scars the structural deviations in the BM trigger basal 
keratinocytes to transform to proliferative phenotype. An abnormal response to persistent 
or repetitive injury to epithelial cells is also suggested to result in fibrosis (128). The 
equilibrium between keratinocyte proliferation and differentiation is disturbed in scar 
tissue (115). Keloid-derived keratinocytes have been shown to be significantly more 
proliferative and resistant to apoptosis than normal skin derived keratinocytes. 
Keratinocytes also play an important role in the development of pathological fibrosis 
through paracrine regulation of fibroblasts like enhancing their proliferation and collagen 
production (115). Activated keratinocytes of hypertrophic scars produce growth factors 
that affect the inflammatory response and endothelial cells. The persistence of activated 
keratinocytes indicates abnormal keratinocyte migration and proliferation and deviant 
epidermal-mesenchymal interactions that delay re-epithelialization (140). Some studies 
imply that the abnormalities in proliferation and differentiation of the keratinocytes cause 
an increase in epidermal thickness and may lead to hypertrophic scar formation (142). The 
increased thickness of epidermis seems to correlate with the severity of the scar (143). 
BM plays a significant role in regulating the cell fate decision of epidermal 
keratinocytes during skin wound healing. Alterations in the structure of the BM reduce 
attachment of basal keratinocytes to their microenvironment and promote them to 
differentiate and to adopt a proliferative phenotype during scar formation with possible 
involvement in pathogenesis of scarring similar to hypertrophic scars. In areas where BM 
is degraded, the differentiation of keratinocytes has been found to be decreased or absent. 
Involucrin, a marker for early terminal differentiation, shows higher expression both in 
keloids and hypertrophic scars compared to normal skin (143). This abnormal early 
terminal differentiation has been found to be associated with disorganization of the 
stratum corneum in keloids. Also the turnover rate of stratum corneum has been found to 
be hastened. The stratum corneum of both keloids and hypertrophic scars shows increased 
transepidermal water loss and/or water-holding capacity compared to normal skin. (143).
Decreased hydration levels have been shown to result in increased proinflammatory gene 
expression in epidermal keratinocytes. Dehydration of the stratum corneum induces 
keratinocytes to produce cytokines, which in turn activate dermal fibroblasts to produce 
collagen (46). 
The depth and frequency of epidermal rete ridge formation has been shown be 
significantly reduced in all scar types compared to normal skin. In young hypertrophic 
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scars the proliferation of keratinocytes, thickness of epidermis and expression of 
keratinocyte activation markers keratins 6, 16, and 17 are increased (141,144). After 12 
months, the increased keratinocyte proliferation and expression of keratin 16 normalize; 
not even abnormal mature scars exhibit increased rates of keratinocyte proliferation.  
In addition to its role as a supportive structure and a barrier, BM also participates in 
signaling during angiogenesis. BM harbours various angiogenesis-modulating molecules, 
growth factors, and cytokines that are released and activated by the breach of BM. 
Laminin degradation exposes angiogenesis-inducing sites. 
Role of angiogenesis 
Early-stage macrophages control induction of granulation tissue and myofibroblast 
differentiation. Mid-stage macrophages play a role in stabilization of vascular structures 
and transition of granulation tissue into scar tissue (145). Both keratinocytes and 
fibroblasts contribute to angiogenesis. Vascular endothelial growth factor (VEGF)-
induced angiogenesis plays a major role in fibrogenesis and hypertrophic scar formation 
(146). VEGF is mainly secreted by macrophages, endothelial cells, keratinocytes, and 
fibroblasts. The expression of VEGF is positively correlated with vascular density and 
negatively with maturation of scar tissue. In the early post-injury scar, expression of 
VEGF in the basal layer of the epidermis is significantly increased. VEGF is able to 
promote inflammatory cell recruitment and increase vascular permeability. VEGF may 
also affect fibroblasts (147).
In hypertrophic scars, pathological angiogenesis is a crucial factor. Many 
angiogenesis-promoting factors have been shown to be abnormal in hypertrophic scars, 
like VEGF, TGF-β1, angiogenin, and thrombospondin (148). Mechanical stretch also 
promotes angiogenesis. In early scar formation, inflammatory factors contribute to 
angiogenesis. Conversely, the newly formed microvessels exhibit endothelial dysfunction 
leading to persistent inflammation. An excessive angiogenic response enhances scar 
formation. The hypoxia environment in hypertrophic scars can further induce 
angiogenesis, which promotes cell proliferation, thus creating greater demand for oxygen 
and promoting circulus vitiosus (148). 
Mechanical stretch/ force 
Dermal fibroblasts are mechanosensitive to mechanical stimuli and stretch of 
fibroblasts leads to the secretion of Leucine-rich alpha-2-glycoprotein (LRG-1). In the 
presence of TGF-β1 LRG1 is mitogenic to endothelial cells and promotes angiogenesis 
(149). Stretch stimulation of dermal fibroblasts triggers signal transduction from ECM 
into cells mediated by β1 integrin in the cell membrane and results in increased synthesis 
of ECM proteins, such as collagen I and III, and elastin, as well as increased production of 
protease inhibitors such as plasminogen activator inhibitor and tissue inhibitor of 
metalloproteinase (150). 
In keratinocytes, stretch stimulation is also transmitted into cells involving interactions 
between β1 integrin and EGFR and induces ERK phosphorylation as is the case in dermal 
fibroblasts. In epidermal keratinocytes, stretch application promotes cellular adhesiveness, 
cell proliferation, and protein synthesis (150). 
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2.3.2 FACTORS AFFECTING WOUND HEALING 
Besides the normal contributors to the complex wound healing, the process is affected 
by multitude of different factors either concerning the local circumstances of the wound, 
or the general condition of the patient, or both. Many of these factors are related to 
impeding the tissue oxygen and nutrition supply. 
Oxygen has a crucial role in energy production. During tissue maintenance and 
homeostasis, oxygen is essential in cell respiration in efficiently producing energy source 
adenosine triphosphate (ATP) in aerobic metabolism, 16 to 18 times more ATP per hexose 
sugar than anaerobic metabolism (151). In wound healing, oxygen facilitates especially 
inflammation and proliferation phases. In inflammation, oxygen is needed as a substrate in 
producing reactive oxygen species (ROS) by neutrophils. ROS help to destroy microbes 
during early inflammation in respiratory burst thereby reducing risk of infection (152). 
Oxygen also has enhancing effects with some antibiotics, such as beta-lactams, 
quinolones, and aminoglycosides (153). 
Paradoxically, in early proliferation phase, hypoxia induces angiogenesis but in later 
stages oxygen facilitates angiogenesis. In ECM production, oxygen is essential in collagen 
synthesis for hydroxylation of proline and lysine. It promotes fibroblast proliferation and 
wound contraction (105). Oxygen also enhances epithelialisation secondary to ECM 
synthesis and increases keratinocyte differentiation (105,152).  
Nutrition is essential in wound healing both as a substrate for energy production and as 
an important source of building blocks or cofactors in different phases of wound healing. 
Glucose is the main source of energy, but fat and proteins can also be consumed. Certain 
amino acids of proteins are particularly important like arginine, glutamine, glycine, and 
methionine for wound healing. Micronutrients, such as trace elements (like zinc, 
manganese, magnesium, copper, calcium, and iron) and vitamins (A, B, C, E, and K) 
influence immune system function, collagen synthesis, and reepithelialisation as cofactors 
in different enzymes (154). Some other important factors affecting wound healing are 
listed in table III. 
Table III. Partial list of additional factors affecting wound healing not listed in the text 
(112,154,155)
Local Systemic
Chemical factors: pH, toxic substances Age, gender
Physical factors: Temperature, pressure, shear forces Diseases: Diabetes, pulmonary diseases, cardio-
vascular diseases, kidney insufficiency, gout,
rheumatoid arthritis
Moisture balance, excessive exudates, urine Medications: steroids, non-steroidal anti-
inflammatory drugs (NSAIDs), anti-rejection 
medications, chemotherapy
Foreign body Lifestyle: Smoking, alcohol abuse, obesity, stress,
nutrition
Necrosis Immunocompromised conditions: Cancer, radiation
therapy, AIDS




2.4 TEMPORARY AND PERMANENT WOUND COVERS 
Literally temporary wound covers are intended for temporary use and to be removed 
and/or replaced with permanent covers integrating to the wound bed. Temporary covers of 
the wound inhibit the invasion of microbes, mechanically protect the wound and aid in 
wound healing. Permanent wound covers assist also in recovering the barrier function 
preventing the dehydration. In burns, traditional dressings are used to temporarily protect 
the wound or assist in treating the infection prior to surgery. After excision or 
debridement, the aim is to prepare the wound bed for skin grafting, and after 
transplantation of a skin graft, to protect the graft or to prevent the infection together with 
moisture balancing. More sophisticated dressings offer a wider range and more complex
solutions temporarily mimicking skin functions. The latest era of nanotechnology in 
bioengineering has enabled adding various components to wound dressings or skin 
substitutes such as nanocomposites of metals, like silver and zinc, with antimicrobial 
properties (156). Other bioactive molecules can also be incorporated to nanofibers, like 
growth factors and cytokines, enzymes, or compounds of ECM to enhance wound healing 
(157). Immunomodulatory properties of the materials aim to reduce inflammatory 
response and avoid foreign body giant-cell formation, as well as rejection of an implant 
(157). One strategy is to modulate macrophage polarization towards the M2 type (158).
Emerging 3D bioprinting allows tailored automated tissue engineering solutions with cells 
either in situ or in vitro printing in the future (159). Some of the different types of skin 
substitutes, both temporary and permanent, are listed in Table IV.
2.4.1 TEMPORARY WOUND COVERS
Biological wound covers/skin substitutes include xenografts, amnion membrane, 
cadaver skin and cultured epidermal allografts. They offer naturally occurring 
biocompatible structures recognized by the host cells. They may elicit immune rejection 
even though they might become partially incorporated to the wound bed and leave 
elements behind assisting wound healing. Amniotic membranes are suggested to have 
anti-inflammatory, anti-microbial, anti-fibrotic, and anti-scarring effects. Cultured 
epidermal allografts provide the wound with a mechanical barrier and growth factors (56),
and the cells also synthesize components of ECM.  
2.4.2 PERMANENT WOUND COVERS/ SKIN REPLACEMENTS 
The use of permanent skin substitute should be safe and effective, preferably also cost-
effective. The choice of the product should be tailored to the needs of the patient. The list 
of other properties desired is long and constantly lengthening. Even though the use of skin 
substitutes is slowly increasing they are not widely used. According to a survey in 2015 
their use was considered essential or at least desirable in treating large burns (160). 
Permanent skin substitutes replace either epidermis dermis or both. Permanent grafts 
need to be integrated to the wound bed even though they may be replaced later by 
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autologous tissue. In dermal substitutes, the vascular ingrowth into the material is essential 
to establish circulation to bring oxygen and nutrition for the cells.  
Permanent epidermal grafts include cultured epidermal autografts, sprays, or sheets. 
Their take rate seems to depend on the type of wound bed: 45–75% when grafted onto 
dermal or neodermal wound bed, 28–47% when grafted onto early granulation tissue, and 
only 15% when grafted onto granulation tissue of chronic wound bed (161). Graft loss has 
been linked with infection, insufficient microcirculation of the wound bed, and poor 
adherence of the graft due to slow formation of anchoring fibrils (161).  
Dermal substitutes or matrices with or without seeded cells are constituted either from 
natural or synthetic polymers.  
Since collagen type I is a natural polymer and also the most abundant protein of human 
dermal ECM, it is a usual constituent of artificial dermal matrix (162). Collagen-based 
scaffolds are known to reduce wound contraction and scar formation and to promote 
epithelialization. Collagen has strong affinity to the soft tissue and blood vessels, and it 
can be replaced with host cells and vessels through acceleration of their penetration into 
the scaffold. The advantage of using collagen resides in its high biocompatibility, 
biodegradability, and weak antigenicity while offering support for cell attachment and 
growth compared with other natural biomaterials. Other natural biopolymers in currently 
commercially available skin substitutes contain gelatin or chitosan (163). Fast degradation 
and low mechanical stiffness limit their clinical use. Other naturally occurring polymers 
used in dermal substitutes include elastin, GAGs, fibronectin, fibrin, silk, and alginates 
(164). The benefit of natural polymers is that they exhibit low toxicity and elicit low 
inflammatory response (164).
One of the synthetic dermal substitutes is Integra®, the most widely used dermal 
substitute and the first FDA-approved artificial skin substitute (165). It is covered with 
0.23 mm thick polysiloxane membrane mimicking epidermis. The silicone layer is stated 
to have vapor transmission characteristics similar to normal epithelium. The two-layer 
construct contains a 2-mm-thick dermal template layer of type I collagen from bovine hide 
and chondroitin-6-sulfate from shark’s cartilage (166). This ADM has been shown to 
contain only modest inflammatory cell infiltrate—primarily macrophages and 
lymphocytes in the early phase after application (167). It has been explained that this 
would rely on the capability of chondroitin-6-sulfate to block aggregation of platelets and 
therefore to reduce pro-inflammatory signaling (166). Studies by Yannas et al. have 
strongly suggested that blocking of wound contraction follows extensive binding of 
myofibroblasts on the surface of the scaffold (168). Chondroitin-6-sulfate has also been 
suggested to bind TGF-β (166). 
The use of chondroitin-6-sulfate increased the resistance to collagenases of the 
material and decreased the need to use extensive cross-linking (165), even though the 
product contains only 8% of dry weight chondroitin-6-sulfate (169) thus delaying the 
degradation of the product. 
Some of the synthetic polymers, such as polylactic-co-glycolic acid, 
polyhydroxybutyrate, and polyethylene glycol, are used as carrier scaffolds because of 
their good mechanical properties (162). Polyvinylpyrrolidone, polycaprolacton, 
polyethylene glycol, and poly lactic acid possess advantageous mechanical properties 
including elasticity and contractibility, similar to those of native skin with less 
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biocompatibility and in vitro and in vivo functionality and performance. There are some 
unsolved challenges, like wound contraction, impaired vascularization, scarring, and high 
cost associated with these products (170).  
2.4.3 DERMO-EPIDERMAL SUBSTITUTES /COMPOSITE SKIN 
SUBSTITUTES 
These substitutes consist of two layers: epidermal cells and dermal substitute with 
fibroblasts. The cells can be either allogenic or autologous. If only allogenic cells are used 
the substitute may only be a temporary cover since the survival of allogeneic cells limited 
to one to two months (171).
The cells of currently commercially available cellular skin substitutes contain only two 
types of cells, keratinocytes and fibroblasts. Regarding the quality of scarring one aspect is 
not to use just any kind of fibroblasts rather than using superficial dermal fibroblasts since 
they have been shown to be anti-fibrotic whereas deep dermal fibroblasts are shown to be 
pro-fibrotic (56). Keratinocytes and fibroblasts alone are nonetheless unable to supply 
sufficient pigmentation, pressure and temperature sensation, immune regulation, excretion, 
perspiration, thermoregulation, protection from ultraviolet radiation, synthetic function, 
and insulation (56). Current major differences between skin substitutes and the skin itself 
include the absence of stable vascular and lymphatic networks, skin appendages (such as 
hair follicles, sweat glands and sebaceous), and hypopigmentation (172). To resemble 
functional skin, melanocytes and Langerhans cells, adipose tissue and nerves, together 
with the vascular ingrowth, still need to be added together with the formation of skin 
appendices. 
In burns the use of skin substitutes does not replace all skin elements and innervation. 
Their deficiency may cause the patient a variety of complications and discomfort, such as 
lack of sensation, perspiration, and motion flexibility (112). The pain in burn wounds may 
also play a role in controlling local inflammation. 
2.4.4 BIOENGINEERED WOUND COVERS 
Bioengineered skin-replacement products may be either temporary or permanent. They 
can be either synthetic, or contain biological constructs, or a combination of both. 
Preference is given to products that are biodegradable containing natural polymers with 
binding sites for cells. The materials are expected to promote the ingrowth of surrounding 
cells or to serve as vehicle and scaffold for transplanted cells facilitating building of the 
new tissue (45). They may also contain growth factors, cytokines, other bioactive 
molecules, and ECM for host cells (173) or even allogeneic or autologous cells producing 
aforementioned. These high-tech products often induce cellular migration of local cells 
into the material or support attachment, proliferation, and differentiation of transplanted 
cells (45,156).  
Artificial bioengineered scaffolds can be even further functionalized by adding 
signaling molecules regulating cell–cell and cell–matrix interactions to enhance matrix 
integration. The material can be cross-linked to resist wound contraction, add tensile 
strength, and reduce or delay degradation. On the other hand, cross-linking may decrease 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5 SCAR ASSESSMENT METHODS 
Scar assessments are needed to evaluate scar severity, make a treatment plan, follow 
up the efficacy of the treatments, and identify the need for modifying the treatments (180), 
but also to identify the risk factors for hypertrophic scars (181).Various tools have been 
used to assess scars but none of alone has yet been proven to be optimal. A gold standard 
is still lacking. In most cases, scars are assessed either with subjective scar assessment 
scales or with scar assessment devices measuring objectively one or more properties of the 
scar, and lately also with the combination of both. 
The advantages of using scar scales are obvious: they are easy to use, inexpensive, and 
time-efficient (175), but their disadvantages are subjective assessments with low inter-
rater reliability (168). The scar assessment devices instead are costly, and their use is often 
time-consuming. Even though devices give objective measures, they are prone to 
interpretation and measurement errors (176). 
2.5.1  SCAR ASSESSMENT SCALES CURRENTLY AVAILABLE
The Vancouver Scar Scale (VSS), also called The Burn Scar Index, is the first 
validated scar scale and one of the most widely used scar assessment scales, both in 
clinical assessments and in research use (182-184). It has been developed for assessing 
burn scars. Four parameters are evaluated with separate scores ranging between 0 and 5: 
pigmentation, vascularity, pliability, and height. The higher the scar scores, the worse the 
scar is. The worst possible scar scores in the original version 14 points and in the amended 
version 13 points. The scale is subjective and the validity and reliability has been shown to 
be intermediate and it lacks the assessment of scar related symptoms. Most of the current 
scar scales and objective scar assessment devices have been compared to VSS in their 
validating process.  
Only a few of the scar scales measure symptoms of the scars such as pain and itching. 
The Patient and Observer Scar Assessment Scale (POSAS), introduced in 2004, is one of 
the first, if not the first, validated scar scale that also takes into account the patient’s 
perspective, and it also includes a patient rating for itching and pain (185). Parameters 
evaluated with the scale are the symptoms (e.g. pain and pruritus) and physical 
characteristics of a scar (e.g. vascularization, pigmentation, thickness, relief, pliability), 
ranked on a 1-10 ordinal scale. In a comparative study of VSS and POSAS, the latter has 
been found to be more reliable for single observers. Even this scale lacks the assessment 
of function or its deficits and the psychological and social aspects (182). 
The Manchester Scar Scale (MSS) is based on three different types of evaluations: 
clinical assessment; rating of photographs; and evaluation of the histological properties of 
the scar. The ratings are combined with a visual analogue scale. Parameters evaluated 
include: color, contour, radiance (matte/shiny), texture, and distortion. This scale is best 
suited for assessing linear scars and it lacks the assessment of scar-related symptoms. 
(186). 
The Stony Brook Scar Evaluation Scale (SBSES) is a photo-based scale and it was 
developed in the context of emergency medicine. The parameters assessed are: color; 
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elevation or depression; width; suture or staple marks; and overall appearance. Scores 
range from 0 to 5 for each parameter. This scale’s inter-rater reliability is good, but it lacks 
the assessment of scar-related symptoms.(184). 
The Hamilton Scale is based on evaluating photographs of the scars. The following 
parameters are assessed: color, vascularity, surface irregularity, and thickness. This scale 
has a good reliability, but it includes a possible disadvantage of distortion of observer’s 
interpretation of the photograph. It also lacks the assessment of scar-related symptoms. 
(182). 
The Seattle Scale is also based on evaluating photographs of the scars. The assessed 
parameters are: pigmentation, surface area, thickness, and height. The ratings also allow 
negative values for certain parameters, such as hypopigmentation or atrophy, to better 
differentiate between different scar types. It lacks the assessment of scar-related 
symptoms.(182). 
The University of North Carolina 4P Scar Scale (UNC4P) was developed to widen the 
spectrum of the qualitative assessment of current scar scales. The “4Ps” of the UNC4P 
include pliability, pain, paresthesias, and pruritus, and the scale of the scar ranges from 0 
to 12. It is designed to be used in combination with another scar scale like VSS (187).
Digital image capturing combined with in-person scar assessment has also been used 
to better classify scarring. A similar method is the Matching Assessment of Scars and 
Photographs (MAPS) that also combines in-person assessments with digital photos.  
Visual Analog Scale (VAS) with scar ranking has been originally designed for 
assessing pain the patient is experiencing with a linear scale from 0 to 10, but has also 
been successfully used to assess patients’ experience of their own scars. (182). 
In addition to the above-mentioned scar-assessment tools, there are also patient-
reported scales measuring health-related quality of life, such as the Patient-Reported 
Impact of Scars measure (PRISM) measuring also physical symptoms (188) and the 
Brisbane Burn Scar Impact Profile. 
Since most of the original scar scales fail to address the symptoms caused by the scar, 
many have been modified to take symptoms into account. Not all the modifications have 
been validated (182). Itching and pain should be measured, but an objective measurement 
tool remains to be developed. 
2.5.2  OBJECTIVE SCAR MEASURING DEVICES 
The following key characteristics of the scar can be measured objectively by various 
scar assessment devices: color in terms of pigmentation and vascularity; biomechanical 
characteristics such as pliability and elasticity, texture; and dimensions such as 
height/thickness, area, and volume of the scar. Pathophysiological disturbances in oxygen 
tension by transcutaneous oxygen tension (tcpO2) in water loss and moisture content 
could also be measured by transepidermal water loss (TEWL) in an open or closed 
chamber system, as well as tissue microstructure of the scar (189,190).  
Color measuring devices 
Color of the scar depends on vascularity of the scar, as well as the pigmentation of the 
skin involved. Inflammation and erythema increase the blood supply of the affected area. 
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Quantity of pigmentation can be measured by the intensity of a specific wave length of 
light reflecting back from the scar with the knowledge of light absorption patterns of 
haemoglobin, melanin, and collagen.  
Devices based on reflectance spectroscopy utilize either tristimulus (three different 
wavelength illumination; regions for red, green and blue) or narrow-band scanning 
reflectance. Some examples of tristimulus-based devices include: Chromameter, Micro 
Color, and LabScan XE. Devices quantifying color with a narrow-band spectrophotometer 
utilize calculations of melanin and erythema index. Examples of such devices are 
DermaSpectrometer and Mexameter. 
Laser imaging may be used for measuring microcirculation in the scar, for example, 
Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), or Laser Speckle 
Imaging (LSI)/Laser Speckle Perfusion Imaging (LSPI) (190). 
Cutaneous perfusion can also be measured light-based SIAscope or by in vivo confocal 
laser scanning microscopy (191). By intravital capillaroscopy it is possible to measure 
capillary density and the structure of vasculature by dermoscopy (190). 
Digital photographs may also be analysed by quantifying color values in computerized 
analysis of two-dimensional (2D) or three-dimensional (3D) photographs (190).
Scar dimensions measuring devices 
Surface area can be evaluated by planimetry or 3D imaging. 
The height or the depth of the scar may be assessed by ultrasound, moulds, or dial 
caliper. Ultrasonography or ultrasound scanning may also include a tissue ultrasound 
palpation system (TULP or TUPS). Examples of TULP devices are PolyU, Aloka Echo 
Camera, and DermaScan-C and DermaScan-A (191). TUPS requires technical training and 
experience in image interpretation and is relatively expensive compared to other 
modalities though. Biomechanical characteristics, such elasticity, stiffness, and pliability 
can be measured by suction, tonometry, torsion, adherence, reviscometry, elastometry, 
ballistometry, dielectric measurements, and bio-impedance. 
Pliability measuring devices 
Devices suitable for measuring the pliability include pneumatonometer, tissue 
tonometer, cutometer, dermal torque meter, and elastometer (191). 
The firmness and/or hardness of the scar can be assessed by durometer, where 
vertically applied load causes indentation measured. Durometers have been used in 
assessing burn scars, but were originally developed for the assessment of scleroderma. 
Their disadvantage is high inter- and intraobserver variability (184). 
Combination devices measuring multiple different properties of the scar are nowadays 
available, such as Dermalab combo.  
2.5.3 PROTEIN PROFILING METHODS 
Different studies have found diverse amounts of proteins in skin using varying 
methods. In the Human Protein Atlas www.proteinatlas.org (status 12.1.2020), based on 
transcriptomic analysis, 14857 proteins are expressed in human skin. This encompasses 
approximately 76% of all human proteins. The major problems when comparing different 
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proteomes is the differences in protein identification techniques (micro-array, 
immunohistochemistry, and mass spectrometry data), differences in anatomical sites and 
disease states.  
The use of proteomic techniques in skin tissue has not proven to be easy due to an 
abundance cross-linking of proteins and high lipid content making isolation and digestion 
of proteins challenging for analyses (192). Proteomics may also be more sensitive and 
precise than previous or traditional methods, buttranslational and clinical significance of 
the findings often remain unclear. 
The Manchester Proteome is one of the newer protein libraries of skin combining 
bioinformatics, systematic reviews, mass spectrometry, and immune-based techniques. It 
has 2948 identified proteins of healthy skin (193). Some proteomic studies have been 
conducted on scars (194,195).
2.6 PSORIASIS 
This chapter provides a very brief overview of psoriasis characteristics and 
pathogenesis that can be related to the (patho)physiology of wound healing. 
Psoriasis is a common chronic inflammatory (autoimmune) systemic disease affecting 
2–3% of adults (196,197). It is characterized by abnormal keratinocyte proliferation, 
aberrant keratinocyte differentiation, and accelerated turnover of epidermal layers (196), 
as well infiltration of inflammatory immune cells (197) and angiogenesis (198). 
Histopathologically typical changes include thickened stratum spinosum and stratum 
corneum, with retained nuclei as parakeratosis. In the suprabasal layer, keratinocytes 
proliferate excessively, whereas the granular layer is missing or abrupted (199). Psoriasis 
is also associated with other co-morbidities such as psoriasis arthritis and cardiovascular 
disease, together with risk factors such as dyslipidemia, higher blood pressure, and higher 
body mass index (197). 
The following pathogenesis has been suggested: The innate immune system in 
psoriasis is dysregulated. Trauma or infection results in release of antimicrobial peptide 
LL37 by keratinocytes. LL37 binds to self-DNA and self-RNA fragments that are released 
from dying or stressed skin cells forming complexes. In turn, these complexes activate 
plasmacytoid dendritic cells (pDCs), which then produce type I interferons (IFN), for 
example IFN-α. Type I IFNs and immune complexes may then activate myeloid DCs. 
Activated mDCs release IL-23 and IL-12, which in turn activate Th17, Th1, and Th22 
cells and their immune pathways. The latter produce cytokines, such as IL-17, IL-22, IFN-
γ, and tumor necrosis factor (TNF). These cytokines stimulate keratinocytes to intensify 
the inflammation characteristic of psoriatic lesion (200). 
Keratinocyte hyperproliferation in psoriasis is possibly due to pro-inflammatory 
cytokines such as TNF, IL17A, and IL-23 produced by infiltrating immune cells like T 
cells, macrophages, and neutrophils (201,202). The cross-talk between epidermal 
keratinocytes and immune cells is disturbed (203). 
Diseases like psoriasis exhibit aberrations in proliferation and differentiation through, 
in part, dysregulation in these epigenetic mechanisms (204). In psoriasis and other 
hyperproliferative skin diseases, integrins are also found in upper layers. 
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Psoriasis shares many immunological similarities with persistent wounding responses. 
Similar to wound-activated keratinocytes, suprabasal keratinocytes in psoriatic skin 
lesions also express high levels of KRT6, 16, and 17, which is considered to be a hallmark 
of psoriasis (19). 
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 AIMS OF THE STUDY 3.
The main goals of this thesis were to evaluate if the different early wound-bed 
treatments have effects on the wound healing process in the early phase, at three months, 
and at the final stage at the one-year time point. 
The main hypothesis was that the use of an artificial dermal substitute would result in a 
better long-term outcome both functionally and cosmetically, whereas the induced 
granulation tissue was expected to result more hypertrophic scarring. The hypothesis in 
study II was that the additional neodermal ECM would have beneficial effects on STSG 
compared to fascially excised wound bed. The hypothesis in study III was that the treated 
sites differ in terms of their protein expression at the latest stage of follow-up, one year. 
 
The objectives/specific aims of the individual studies were: 
 
Study I  
To assess how the use of different wound-cover materials during early wound healing 
affects the wound healing process within one year of an excised deep burn wound, using 
clinical, histological, and immunohistochemical analyses. This study focused on overall 
wound healing and scar assessment. 
 
Study II  
To evaluate how the pre-treatment of the excised wound bed, compared to no 
treatment, affects the vascularization, inflammation, and proliferation of the cells in the 
transplanted STSG one week after grafting and  to evaluate the proliferation of the cells 
three months after grafting, focusing on computer-assisted image analysis of 
immunohistochemical findings.  
 
Study III  
To examine and compare the long-term effect of three different dermal compositions 
on transplanted STSG at the 
protein level one year after surgery 
of a deep burn wound. This study 
focused on one-year follow-up 
results. 
To study the function and role 
of DNAH10, also with another 
group of patients (psoriasis) with 
similar features to wound healing, 
such as inflammation and epithelial 
hyperproliferation. 
  
Figure 7. Experimental design 
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 MATERIALS AND METHODS 4.
4.1 PATIENTS 
4.1.1 BURN PATIENTS 
Ten patients with deep large burns admitted to Helsinki Burn Centre were recruited to 
participate in the study. The inclusion criteria were age between 17 and 70 years and deep 
burns over 20% of total body surface area on the anterior side of the body.  
Burn patient demographics 
In studies I and II the age range of the patients was 19–58, mean 36.8 ± 4.0 years at the 
time of the injury. Nine (90%) patients were men and one (10%) a woman. Total burned 
surface areas ranged from 22–45%, mean 35.8 ± 2.4%. 
The inclusion criteria were: age between 17 years and 70 years, the size of the deep 
burn over 20 % TBSA with possible test sites on the anterior side of the body to minimize 
shearing and maseration of the skin grafts. All burn patients received the same treatment, 
only the order of the materials used was randomized by simple randomization with no 
blinding.
Due to cost reasons in study III the samples only of four patients from study I at one 
year time point were used in assessments in study III. These four patients were selected 
due to technically best quality one year samples. 
4.1.2 PSORIASIS PATIENTS 
The age range of patients was 20- 65 years, mean 48,75 years. The samples of four 
patients were used for this study. Samples were originally collected for another study 
4.1.3 HEALTHY CONTROLS 
The age of control participants varied between 45 and 69 years with mean of 59,33 
years, all female. Samples of the three healthy control participants were also obtained 
originally for another study. Ethics 
All participants or their relatives in these studies provided a written informed consent 
adherent to Guidelines of Helsinki Declaration and the studies were approved by the 
Research Ethics Committee of Helsinki University Hospital (DNro 101/E6/2000). 
4.2 WOUNDS AND WOUND COVER MATERIALS 
4.2.1 BURN WOUND TYPE AND LOCATION 
Nine of the patients had flame burns and one had a burn from an electric arc. They all 
had deep third-degree burns needing fascial excision. In our burn-wound model the burned 
necrotic tissue from the anterior side of the body was removed tangentially on fascial level 
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within five days of the injury. The test areas selected for the study were located mainly on 
the chest area or chest/upper abdomen. For one patient, the test area was on the left medial 
thigh and for another patient on the right medial thigh. The test area was 10x15 cm, and 
was divided into three consecutive sections of 5x10 cm. 
The three sections received a different cover material: one was covered with split 
thickness skin graft (STSG) right after excision; one with acellular dermal matrix (ADM); 
and one with a temporary wound cover of viscose cellulose sponge inducing granulation 
tissue (IGT) formation. The order of cover materials in each patient was randomized. 
The STSGs were obtained with air driven Zimmer dermatome with setting of 8/1000 
of an inch equalling around 0.2 mm of thickness. The STSGs in test areas were not 
meshed and they were attached with staples. 
The artificial dermal substitute used in this thesis is Integra®, a two-layer construct. 
The upper layer is made of silicone and it functions as an artificial epidermis before it is 
peeled off or before it detaches from the underlying dermal part. The lower layer consists 
of bovine type I collagen and chondroitin-6-sulfate, a glycosaminoglycan from shark’s 
cartilage, which is chemically cross-linked. In these studies, the artificial dermal template 
was placed on an excised wound bed and attached with staples. After two weeks, the 
silicone layer was removed and replaced with an STSG. 
Viscose cellulose sponge Cellonex™ (Vivoxid Ltd, Turku, Finland) contains 4–6 g of 
cellulose per 100g of viscose solution and it includes supportive cotton fibres about 20% 
of the weight of cellulose. The material has a porous structure with thin pore walls and the 
cells are able to migrate into the material. This temporary wound dressing was changed on 
days 3 and 7 and it was removed on day 14 and replaced with an STSG. 
The surrounding areas were covered with meshed split thickness autografts. STSGs 
were covered with Surfasoft® monofilament polyamide woven sheet (Mediprof, 
Bleijswijk, the Netherlands) attached with staples. No local antibiotics or silver was used 
in test areas or their immediate proximity. In other areas, antimicrobial topical agents were 
used if needed. 
4.2.2 TIMELINE OF THE STUDY  
Figure 8. Timeline of the study. Illustration copyright Sole Lätti. 
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The burns were operated within five days of injury. During the initial debridement 
operation on day 0 of the study, a test area with three treatment sections measuring 5x10 
cm, each adjacent to each other, was selected on the anterior side of the body within the 
deep third degree burn. After tangential excision on the fascial level, one of the treatment 
sections received a split thickness skin graft, another an artificial dermal substitute and the 
third was covered with a viscose cellulose sponge. At the times of changing the cellulose 
sponge, on days 3 and 7, punch biopsies and photographs of all treatment sections were 
also taken. 
On day 14, the silicone layer of artificial dermal substitute was removed, the cellulose 
sponge was removed, and punch biopsies and photographs of all treatment sections were 
taken. Then, the two treatment sections without STSGs were covered with STSGs. 
On day 21, as well as three and twelve months after primary operation, punch biopsies 
and photographs of all treatment sections were taken. 
At three and twelve months after surgery, the Vancouver Scar Scale assessment was 
performed by an occupational therapist to evaluate the cosmetic and functional outcome of 
the treatment sections.  
4.2.3 SKIN SAMPLES (I, II, AND III) 
Skin samples of burn patients were obtained by 3–4 mm punch biopsies of the wound 
bed after tangential fascial excision of the burn and of all treatment areas 3, 7, 14, and 21 
days, as well as 3 months and 12 months, after the primary operation. 
The samples were fixed in 10% buffered formalin and after fixation embedded in 
paraffin.  
For study I, all samples were used in analysis. In study II, samples from one week after 
transplantation of STSG (meaning day 7 for test areas of STSG alone and day 21 for test 
areas with ADM and IGT) and three months after primary operation were assessed. In 
study III, the samples of four patients at 12 months were analysed. 
In study III, the skin samples of psoriasis patients were harvested with an air-driven 
dermatome with a setting of 4–6/ 1000 inches both from lesional and non-lesional sites.  
Healthy control skin was obtained from reduction mammoplasties or microvascular 
free-flap surgeries. These samples were primarily collected for another study, and were 
fixed in 10% buffered formalin and after fixation embedded in paraffin. Then, 5μm-thick 
sections of these formalin-fixed paraffin-embedded samples were cut and stained 
immunohistochemically for evaluation of DNAH10 expression using the same staining 
protocol as detailed below for the burn-patient samples. 
Stainings of the skin biopsy samples (I, II, and III) 
In study I, slides of all samples were stained with standard hematoxylin and eosin 
(HE). 
In studies I, II, and III, samples were stained with various immunohistochemical (IHC) 
stainings using the following protocol: 
After de-paraffination, the samples underwent four cycles of five and half minutes of 
heat-induced antigen retrieval with citrate-buffer (Citric acid monohydrate Merck and 
distilled aqua) pH 6.0 in a microwave oven. After cooling and washes with TBS, the 
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samples were blocked for endogenous peroxidase with 0.5% H2O2 in methanol for 30 min. 
Non-specific binding was blocked using 10% normal goat serum in TBS buffer at room 
temperature for 2h. The samples were then incubated in primary antibody solution 
overnight at +4ºC. On the next day, after washes with TBS + 0.025% Triton, dilutions of 
secondary antibody in 0.5% BSA-TBS were added and the slides were incubated for 30 
min at room temperature. The samples were then washed and incubated in ABC-complex 
followed by washes and incubation in aminoethyl carbazole (AEC) solution. After colour 
development, the slides were washed in lukewarm tap water and counterstained with 
Mayer’s haematoxylin for 1 minute. Samples were then coated with Aquamount mounting 
medium. 
Protocols varied according to the primary antibodies used. Instead of using citric acid 
in microwave treatment for IHC of collagen type IV, the deparaffinised slides were treated 
with trypsin digestion with 0.5% trypsin in PBS and then washed with PBS. In IHC of 
CD31, protease type VIII digestion was used instead of citric acid in microwave treatment. 
In MIB-1 antibody IHC, the endogenous peroxidase was not blocked. In alpha-SMA 
staining no previous citric acid in microwave was needed. 
In study I, the staining of the samples was assessed with a semi-quantitative scale from 
0 to 3 by two pathologists. In study I a 25-point Chalkey eyepiece graticule was used 
assess angiogenesis, particularly the vessel density. The calculations were made based on 
the average from assessment of three hot spots, where the number of points in the grid that 
hit stained vessels is counted. In studies II and III, the stained slides were scanned and the 
images were analysed as described in Chapter 8. 
Table V. List of antibodies used in the studies. 
Used in study Staining/ antibody Vendor Dilution of 
primary 
antibody 
I, II CD31 as marker for endothelial cells DakoCytomation, Glostrup, 
Denmark 
1:100
II CD163 a marker for type M2 
macrophages, clone 10D6
Novocastra Laboratories Ltd, 
United Kingdom 
1:200
I Alpha SMA for smooth muscle cells 
and myofibroblasts, 6582 BioMakor, Israel 
1:20,000
I, II, and III MIB1 a Ki67 clone as a marker for 
proliferation, M7240 DakoCytomation 
1:500
I, II collagen type IV a marker for 
basement membrane, M0785 DakoCytomation
1:100
III CASP14, a marker for keratinocyte 
differentiation, HPA027062 Sigma-Aldrich 
1:1000
III DNAH10 a marker for axonemal 




ASSESSMENT AND ANALYSIS METHODS 
4.2.4 VANCOUVER SCAR SCALE 
Burn Scar Index/Vancouver Scar Scale is widely used clinical assessment for different 
kinds of scars. Four different qualities of scar were assessed by an occupational therapist.
In study I, the assessment was performed by an occupational therapist treating scar 
problems. All the test areas were assessed twice, three months and twelve months after 
excision of the burn. 
Table VI. Original Burn Scar Index assessment parameters and the criteria for values.  
Pigmentation M (0–2) Normal 0 
 Hypopigmented 1 
 Mixed 2 
 Hyperpigmented 3 
Vascularity V (0–3) Normal 0 
 Pink 1 
 Red 2 
 Purple 3 
Pliability V (0–5) Normal 0 
 Supple 1 
 Yielding 2 
 Firm 3 
 Banding 4 
 Contracture 5 
Height H (0–3) Normal (flat) 0 
 0–2 mm 1 
 2–5 mm 2 
 >5 mm 3 
4.2.5 PROTEOMICS 
Tissue microdissection  
Sample preparation: paraffin-embedded three formalin-fixed10-μm-thick sections from 
each sample block were deparaffinized by incubation at room temperature in xylene for 10 
min. After deparaffinization, tissue sections were rehydrated with a graded series of 
ethanol and briefly air-dried.  
Microdissection: Skin epidermis and dermis including skin appendices were dissected 
with the PALM MicroBeam laser capture microdissection system (Zeiss, Göttingen, 
Germany) and collected into AdhesiveCap opaque tubes (Zeiss). The tissue was lysed in a 
buffer consisting of 0.3 M Tris-HCl, pH 8.0; 0.1 M DTT; 0.5% (w/v) polyethylene glycol 




Sample purification was performed via methanol/chloroform protein precipitation. 
Protein reduction and alkylation was performed in 100 mM Tris (pH 8.0) containing 5% 
sodium deoxycholate by adding 5 mM DTT and 10 mM iodoacetamide for 20 min at room 
temperature. Protein digestion was carried out by diluting the solution 5 x with mQ-H2O, 
before adding 400 ng trypsin (Pierce, ThermoFischer Scientific, Waltham, MA) per 
reaction and incubating overnight at +37°C. Trifluoroacetic acid was added to a 
concentration of 0.5% to stop the digestion. The peptides were purified using C18 
StageTips (3M Empore, Eagan, MN) and then analyzed on an Ultimate 3000 RSLCnano 
(Dionex, ThermoFisher Scientific) nano-LC system with a C18 cartridge column (Dionex) 
and an in-house packed (3 μm ReproSil-Pur C18AQ particles, Dr. Maisch HPLC GmbH, 
Ammerbuch, Germany) 50 cm 75 μm ID emitter-column (New Objective, Woburn, MA) 
using a 60 min 8–50% B gradient where buffer A was 0.1% formic acid in water and 
buffer B was 0.1% formic acid in 80% acetonitrile. Separated peptides were then eluted at 
200 nl/min (spray voltage 2.4 kV) to a Q Exactive Plus (ThermoFisher Scientific) mass-
spectrometer operating with a top-5 MS/MS strategy with a 0.6 s cycle time. Dynamic 
exclusion was set to 30 s. Only charge states +2 to +6 were analyzed. MaxQuant 1.4.0.8 
software package was used to identify and quantify the raw data. Search was performed 
against the UniProt (www.uniprot.org) human database using the tryptic digestion rule. 
Analysis of proteomics data: Each sample of raw proteomic data was first normalized 
to the dissected tissue area, and then normalized to its detected proteins’ average intensity. 
These sample tissue area- and intensity-normalized values were then used in subsequent 
analyses using a statistically significant cut-off of p<0.05 for each identified protein in any 
comparison between groups. Gene Cluster 3.0 software4 was used for clustering of 
proteins and sample groups and heat map visualizations were produced by using Java 
TreeView 1.16r4 software. 
4.2.6 IMAGING AND IMAGE ANALYSIS 
Scanning of slides 
For study III, the immunohistochemically stained slides from the samples were 
scanned with a 20x magnification microscope by the Digital microscopy and molecular 
pathology unit at the Finnish Institute for Molecular Medicine (FIMM, Helsinki, Finland). 
Microscopy images were viewed using the Panoramic Viewer software (3DHISTEC 
Ltd, Budapest, Hungary). Snapshots of approximately 60–65x magnified views were 
captured. 
Image analysis  
For studies II and III, the captured images of immunohistochemically stained slides 
were analysed by authors with FIJI ImageJ software (205). Macros for automated 




4.2.7 STATISTICAL AND BIOSTATISTICAL ANALYSES, TOOLS AND 
DATABASES 
In study I, the nonparametric Friedman test was used for detecting differences between 
the effects of different wound-bed treatment materials in certain sectors of wound healing: 
in inflammatory cells, in angiogenesis, in numbers of epidermal cell layers, in type IV 
collagen of basement membrane, in myofibroblasts, and in VSS.  
Spearman correlation test was used to analyse the correlation between fibroblasts and 
myofibroblasts.These analyses were performed by using Number Cruncher Statistical 
Systems-computer program (NCSS). 
Page’s trend test with R statistical software using package ‘concord’ was used for 
analyzing keratinocyte proliferation. For the rest of the analyses IBM SPSS version 19 
computer program was used. 
In study II, two-sided Student’s t-tests were used to discover possible differences 
between different wound covers at one week and three months after skin grafting.  
To calculate linear correlation (Pearson) between CD163+ macrophages and CD31+ 
endothelial cells GraphPad Prism 5.0 software was used. 
In study III after normalization to their respective sample area, the identified proteins 
in the proteomics dataset that met the p<0.05 cutoff in normalized expression and were 
associated with biological functions and/or diseases in Ingenuity’s Knowledge Base were 
considered for the analysis. Right-tailed Fisher’s exact test was used to calculate a p-value 
determining the probability that each biological function and/or disease assigned to that 
data set is due to chance alone. 
If not otherwise stated, statistical analyses were performed using Student’s-t-test for 
pairwise comparisons. P-values less than 0.05 were considered significant. 
This was used to calculate a p-value determining the probability that each biological 
function and/or disease assigned to that data set is due to chance alone. The proteins that 
met < 0.05 cut off for p-value were included in the analysis.  
Biostatistical tools such as Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics, 
Redwood City, CA) and TRANSFAC® were used in study III to analyse proteomic and 
sequencing transcriptomic data acquired from mass-spectrometry of the samples. Here 
both pathway analysis and upstream and downstream protein networks were generated 
using IPA. 
TRANSFAC® is a database for eukaryotic transcription factors that was used in this 
study to predict potential transcription factor binding sites.The use of these bio-statistical 
pathway analyses is based on existing databases. The pathway here refers to an artificial 
simplified model of a process in cells or tissues. The model may involve signaling 
pathways, related proteins, identifying distinct cellular processes, or diseases with 
association to identified proteins or genes. 
 
54
RNA sequencing data comparison 
We collected and compared the fold-change values of differentially expressed dynein 
and kinesin genes from psoriatic patients’ lesional, non-lesional areas and from the control 
samples of the 5’-end targeted RNA-sequencing data from Tervaniemi et al. (206) 
published data of psoriatic samples with other published studies. 
4.2.8 CELL STIMULATION EXPERIMENTS  
Cell cultures and cell stimulations (III) 
For study III, human primary keratinocytes for cell cultures were obtained from 
discarded full thickness skin of reduction mammoplasties and abdominoplasties. A written 
informed consent was obtained from all donors and the study was conducted according to 
the Helsinki Declaration. The primary keratinocytes were isolated from the epidermis.  
Keratinocyte isolation protocol of the collected skin samples 
The adipose tissue left on the skin samples was removed with a scalpel. The samples 
were minced into small pieces and rinsed carefully with phosphate-buffered saline (PBS). 
In order to separate epidermis from dermis using enzymatic digestion the minced pieces 
were placed into 6-well-plates filled with solution of 2 ml PBS and 2 ml of solution of 
lyophilisated matrix metalloproteinase, dispase (Dispase, Roche Diagnostic Deutschland 
GmbH, Mannheim, Germany), 2 mg diluted to 10 ml of PBS and incubated overnight in 
the fridge + 4ºC. After incubation the epidermis was peeled off from the dermis with 
needles. The isolated epidermal layer pieces were placed in a test tube containing 0.1% 
trypsin-PBS solution and incubated at 37ºC for two minutes to detach the keratinocytes 
from the epidermis. The tube was vortexed cautiously until the clear trypsin became 
blurry. The gained single-cell suspension was transferred to another test tube using a cell 
strainer. To inhibit further trypsinization, a solution containing 10% of fetal bovine serum 
(FBS) – Dulbecco Modified Eagle Medium (DMEM) was added and then the new 
suspension was centrifuged for 5 minutes at 350 G. The supernatant was gently removed 
with a pipette and 5 ml of GIBCO’s keratinocyte serum-free medium (KSFM) supplied 
with growth supplement and 1% penicillin-streptomycin was added and the suspension 
was centrifuged for 5 minutes at 350 G. Cells were counted and then the suspension was
seeded on rat-tail collagen I coated cell culture flasks. 
The freezing and thawing protocols of the cell suspension 
Approximately 900 μl of cell suspension was transferred to each 1 ml cryovial 
containing 50 μl of dimethyl sulfoxide (DMSO) and 50 μl of 100% FBS. DMSO was used
as a cryoprotectant to reduce ice formation and to prevent cell death during the freezing 
process. The cryovials were frozen in a cooler of −80°C for 24 hours and then stored in 
liquid nitrogen. 
The cryovial containing the frozen cells from liquid nitrogen storage was thawed either 
in the incubator at 37°C or in the 37°C water bath. The thawed cells were transferred to a 
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Nunc centrifuge tube and pre-warmed complete growth medium was added. The cell 
suspension was gently centrifuged 200 × G for 3 minutes. After centrifugation, the 
supernatant was decanted without disturbing the cell pellet and replaced with new 
complete growth medium. A sample was taken for cell counting and the rest of the cells 
were re-suspended and transferred to a rat-tail collagen I coated cell culture flask for 
culturing. 
Cell culturing 
For study III both passages three and four were used. The isolated frozen primary 
human keratinocytes were cultured in defined keratinocyte serum-free growth medium 
(10744019, ThermoFisher Scientific, Gibco) for two passages and then passaged to glass 
slides coated with type I collagen for mitomycin C experiments. The keratinocytes were 
cultures for three passages and then passaged to 6-well plates for cell stimulation 
experiments.
Protocol for mitomycin C treatment experiment for the fluorescence 
immunocytochemistry 
For cell cycle arrest, 5μg/ml mitomycin C (Merck KGaA, Darmstadt, Germany) was 
used. The cultured keratinocytes of third passage (P3) on glass slides coated with type I 
collagen were incubated with 5μg/ml mitomycin C for three hours. The control group was 
incubated with defined keratinocyte serum-free growth medium under the same 
circumstances. Cell cultures on glass slides were then washed with culture medium and 
incubated at 37°C for 72 hours.  
Protocol for mitomycin C treatment experiment for the Western Blotting 
The cultured keratinocytes (P3) on glass slides coated with type I collagen were 
incubated for three hours: one group with 5 μg/ml mitomycin C and the control group 
without mitomycin C. Then the wells of the glass slides of both groups were washed with 
culture medium and then incubated with fresh medium at 37°C for 24 hours. Western 
blotting was then performed to detect the differences in DNAH10 expression.  
Cell stimulation protocols 
For cell stimulation experiments, proinflammatory cytokines TNF-α and TGF-β1 were 
both from PeproTech PE Ltd, London, UK. The isolated frozen primary human 
keratinocytes were thawed and cultured as described above. After a third passage, the 
keratinocytes were passaged to 6-well plates (ThermoFischer Scientific) and then 
incubated. Two 6-well plates were used for four different groups, 3 wells for each group, 
approximately 3 million cells/ well. On the second day, the defined keratinocyte growth 
media was changed to Epilife. On the third day, the cells were kept in the incubator for 
growing. On day four, the media (Epilife ThermoFischer Scientific) of group one was 
changed. For stimulation of group two, 10 mg/ml of TGF-β1 was added with the fresh 
media. For stimulation of group three, 50 ng/ml of TNF-α was added with the fresh media. 
For group four, 10 mg/ml of TGF-β1 and 50 ng/ml of TNF-α was added with the fresh 




Immunocytochemistry, immunofluorescence microscopy of treated cell 
cultures and Western blotting 
Table VII. Antibodies 
Primary P, Secondary S Staining/ antibody Vendor Dilution of 
antibody
Immunocytohistochemistry
P DNAH10 a marker for 
axonemal heavy chain dynein 
10, rabbit IgG HPA039065 
Sigma-Aldrich 1:500
S Alexa Fluor 555-conjugated 
donkey anti-rabbit IgG A-
31572 
ThermoFisher Scientific 4 μg/ml
ProLong™ Gold Antifade 




P anti-pan-actin for loading 
control 
Thermo Fisher Scientific 1:500
S goat anti-rabbit 800CW and 




To detect the fluorescence signals we used immunofluorescence microscope EVOS ™ 
FL Imaging System (ThermoFisher Scientific). 
For Western blotting to detect DNAH10 in mitomycin C experiments, the cell lysates 
of the two groups were collected into Laemmli Sample Buffer (Bio-Rad) and then 
separated by polyacrylamide gel electrophoresis (Bio-Rad). The proteins were then 
transferred onto Whatman nitrocellulose membranes (Sigma-Aldrich) and the non-specific 
binding to membranes was blocked in 5% BSA solution (Sigma-Aldrich). The 
fluorescence signals were detected using the Odyssey reader (Li-Cor Biosciences). 
Western blotting and fluorescence detection were also used in analysis of the effect of pro-
inflammatory cytokines TNFα, TGF-β1, and their combination, on the expression of 




5.1 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
In study I, hematoxylin and eosin staining of the first biopsy samples taken in the 
primary operation showed mainly muscle, some fascia, and some adipose cells. The 
samples were assessed by two pathologists with a semiquantitative scale from 0 to 3. 
5.1.1 INFLAMMATION 
Inflammation, the amount of different types of leucocytes before covering the wound 
bed with split thickness skin graft, was higher in cellulose sponge treated granulating 
wound beds compared to ADM and control (C) groups. Neutrophils were highest in 
numbers on day 7 in cellulose-sponge treated areas of all test groups (p=0.0008, IGT mean 
1,45± 1,12 standard deviation (SD), C mean 0,20 ± 0,63 SD, ADM mean 0,00 ± 0,00 SD.
The number of macrophages increased until day 14 in all test groups and the ADM group 
continued to rise until day 21. The same profile of increase was seen for lymphocytes. On 
days 7 and 14 IGT group showed highest numbers of lymphocytes of all test groups (on 
day 7 p= 0,03, IGT mean 1,20± 1,03 SD, C mean 0,38 ± 0,46 SD, ADM mean 0,20 ± 0,42 
SD, on day 14 p=0,0029 , IGT mean 1,22± 0,71 SD, ADM mean 0,350± 0,41 SD and C 
mean 0,30± 0,46 SD). Similarly, the proliferation of inflammatory cells was highest for 
cellulose-sponge treated wound beds on day 14, whereas the other two treatment groups 
showed a minor increase in inflammatory cell proliferation on day 21 (on day 14 p= 0,009, 
IGT mean 1,900 ± 1,1972 SD, C mean  0,750 ± 0,4249 SD, ADM mean 0,700 ± 0,4830 
SD). Only occasional inflammatory cells were detected at later time points in any of the 
test areas. During the whole follow-up period, eosinophils and giant cells were only 
occasionally detected, so no allergic or foreign-body reactions as giant cell granulomas 
were seen. 
In study II, the amount of anti-inflammatory repair M2 phenotype macrophages in 
STSGs was assessed one week after transplantation. The STSGs on IGT presented the 
most CD163 positive staining compared to the STSGs in the other two test areas 
(p=0,0002 between IGT and ADM, p=0,0269 between ADM and C, IGT mean 0,5184±
0,4032 SD, C mean 0,3901± 0,4002 SD, ADM mean 0,2190 ± 0,257 SD). 
5.1.2 PROLIFERATION 
In studies I and II, the proliferation phase from day 3 to day 21, overlapping with the 
remodelling phase, several measures were assessed, including: endothelial cells CD31, 
hotspots in Chalkley count, fibroblasts and myofibroblasts, pericytes/smooth muscle cells 
in blood vessels (α-SMA), keratinocytes MIB-1 and fibroblasts MIB-1 and basement 




In study I, the single endothelial cells were detected from day three onwards. On days 
seven and fourteen the IGT group expressed the highest density of new capillaries of the 
test areas (on day 7 p= 0,007, IGT mean 4,7996 ±1,2392 SD, C mean 4,3330 ±1,2668 SD 
ADM mean 3,2331 ±0,6673 SD, on day 14 p= 0,01, IGT mean 5,666 ±1,7213 SD, C mean 
4,5996 ±1,7414 SD, ADM mean 4,4328 ±2,1548 SD).   The density of vessels was 
assessed by using Chalkley count. In this “hot spot” counting of new capillaries of the 
neodermis including also the dermal component of the STSG, the ADM group showed the 
highest density (of capillaries) by the third week (p=0,032, ADM mean 6,4331 ±1,7429
SD, C mean 5,8297 ±2,1926 SD, IGT mean 5,0297 ±1,6174) . After STSG 
transplantation, the capillary density hot spots decreased in these areas. 
In study I, the least smooth muscle cells were seen around vessels in the ADM group 
from day seven until day fourteen. The number of smooth muscle cells in the ADM group 
doubled thereafter and stayed that numerous until the end of the follow-up with 
comparable numbers to the other test areas. 
In study II, one week after STSG transplantation, the STSGs in the IGT group showed 
the most CD-31 positive area (p=0.0453, IGT mean 2,26 ±  1.574 SD, ADM mean 1,697 ±
1.095 SD, C mean 1,293 ± 0.875 SD as well as largest average vessel size (p= 0,0022,
IGT mean 83,4700 ± 66.5100 SD, ADM mean 42.1800 ± 42.1400 SD, C mean 51,8000 ±
35.9500 SD) and the highest vessel density (not significant) compared to the other groups. 
Epithelialization results are shown combined in remodelling section. 
Fibroplasia 
In the study I the numbers of fibroblasts were highest in IGT group on days 14 and 21 
whereas the amount of myofibroblasts was the highest on same days in the control group 
with only significant difference in myofibroblasts on day fourteen (p= 0,012, C mean 
1,500 ± 1,1728 SD, IGT mean 0,778 ±0,833, ADM mean 0,556 ±0,7265). 
In the study II the fibroblast proliferated at three months in control group the most, 
(almost five times more) compared to the other test groups. In study I in assessment of 
total fibroblast proliferation ADM group showed the most proliferating fibroblast 
compared to the other test groups with no significant difference. On days seven and 
fourteen the control group showed the most MIB-1 staining compared to the other test 
groups with significant difference (on day 7 p= 0,030, C mean 0,667 ± 0,7071 SD, IGT 
mean 0,500 ± 0,500 SD, ADM mean 0 ± 0,00 SD , on day 14 p= 0,008, C mean 0,700 ± 
0,6325 SD, ADM mean 0,050 ± 0,1581 SD and IGT mean 0,200 ± 0,4216 SD). The 
highest MIB-1 staining was seen on day 21 with almost equal amounts both in ADM and 
IGT groups. 
In general, the most fibroblast and myofibroblasts were detected on day 21, at the time 
the fibroblasts also proliferated the most. In a semi-quantitative scale there seemed to be 
more myofibroblasts present than fibroblasts on day 21. 
5.1.3 REMODELING PHASE 3 WEEKS TO 12 MONTHS  
In study I and II the inflammatory cell proliferation was still detectable on day 21, also 
macrophages, also with phenotype M2 CD163 positive cells, were present in all test areas 
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together with a few lymphocytes. Thereafter there was a permanent reduction of 
inflammatory cells in all test areas.  
The numbers of CD31 positively staining endothelial cells were reduced after day 21 
in all test areas but the amount smooth muscle cells in vessels decreased only a little.  
The amount of fibroblasts and myofibroblasts decreased gradually from three weeks 
towards 12 months with scarce fibroblasts and myofibroblasts in all test areas. 
On day 21, a week after STSG transplantation, the dermal cell proliferation was higher 
in STSGs in both AMD and IGT groups compared to the control group (p= 0,0329 
between IGT and C, C mean  1,112 ± 1,077 SD, ADM mean 1,949 ± 1,897 SD, IGT mean 
1,869 ± 1,212 SD) . By three months the proliferation of dermal cells in the control group 
increased whereas the in the other two groups it decreased with statistically significant 
differences (p= 0,0008 between C and ADM, p= 0,0013 between C and IGT, C mean 
2,345 ± 3,988 SD, ADM mean 0,2569 ± 0,2466 SD, IGT mean 0,2899 ± 0,3345 SD).
In study II the proliferation of keratinocytes in STSGs was assessed one week after 
grafting. The keratinocytes of STSGs on IGT group proliferated more compared to the two 
other groups (p= 0,0003 between ADM and IGT, p< 0,0001 between C and IGT, IGT 
mean 5,725 ± 3,956 SD, C mean 1,708 ± 1,484 SD, ADM mean 2,028  ± 2,59 SD). The 
proliferation rate evened out and decreased by three months. In study III at twelve months 
follow-up the keratinocytes proliferated the most in IGT group and the least in ADM 
group with statistically significant differences (p=0,0025 between ADM and IGT, IGT 
mean 14,59 ± 7,2759 SD, C mean 12,33 ± 8,8377 SD, ADM mean 10,35 ± 5,7116 SD).
One week after grafting the STSGs on IGT group showed the most and the ADM 
group the least epidermal cell layers of the test areas but the difference was not significant. 
The number on keratinocyte cell layers decreased from three months to twelve months. 
In study I and III the BM component collagen type IV was assessed. The staining in 
STSGs was low or non-existing in most of the samples already from day three onwards; in 
control group it was only approximately 40 % of the maximum staining at one-year 
follow-up (unpublished data).  
One week after grafting the staining of type IV collagen in STSGs on IGT group were 
lower compared to the other test groups, whereas on ADM group it stained the most 
(unpublished data). At three months the amount of collagen type IV was at the lowest. The 
increase in staining from three months to twelve months was substantial in all groups 
showing as almost a continuous line in most of the samples. The STSGs of ADM group 
showed the most staining of collagen type IV at twelve months compared to the other test 
areas (p=0,0168 between ADM and C, p=0,0189 between ADM and IGT, ADM mean 
0,1197 ± 0,08018 SD, IGT mean 0,0801 ± 0,07974 SD, C mean 0,08875 ± 0,04161 SD).
In study III the differentiation of keratinocytes in STSGs was assessed by staining with 
CASP14. STSGs on IGT group showed the least and control group the most staining at 
one-year follow-up (p=0,0395 between C and IGT, IGT mean 10,65 ± 7,026 SD, C mean 
15,65 ± 10,51 SD, ADM mean 12,11 ± 13,36 SD). 
DNAH10 staining at twelve months showed the least staining in epidermis of the 
control group with statistically significant differences compared to the other two test 
groups (p=0,00789 between ADM and C, p=0,00024 between C and IGT, ADM mean 




The original Vancouver Scar Scale (VSS) was used for scar assessment three months 
and twelve months after primary surgery. There were no significant differences between 
materials in either time point. See Table VII. None of the materials scored high in any of 
the parameters assessed in either time point.  
Of the assessed parameters pigmentation and pliability improved the most between the 
follow-ups.  
In pigmentation the ADM group scored very low and showed no changes, whereas 
IGT group and control group improved equally. The IGT group showed lower score in 
three month’s follow-up though. 
In pliability assessments the control group improved the most in mean values but the 
IGT group gained the lowest scores. ADM group had the highest scores at three months 
but also improved the most by twelve months. IGT group and control group performed 
very similarly and gained very low final scores. 
In vascularity assessments the IGT group improved the most and gained the best 
scores. The control group improved the least, but the ADM group received the worst final 
scores. 
The height of the scar was the only parameter that worsened during the course of time. 
All treatment sections scored the same. This occurred only in one patient of the series and 
equally in all materials. 
The overall scores of VSS mean values improved for all materials from 3 to 12 
months: in induced granulation tissue sections from 2.9 to 0.8, in STSG alone sections 
from 2.5 to 0.8 and in artificial dermal matrix sections from 2.5 to 1.3. In overall scores at 





















































































5.3 PROTEOMICS  
In study III protein content of one-year follow-up samples of four burn patients 
were analysed with mass-spectrometry. 481 proteins were identified out of which 
131 proteins were epidermal and 181 were dermal proteins. The proteins not 
detected in all the samples were not counted. 
The validation of the correct microdissection was performed by blind clustering 
analysis of all samples. As a result, the proteins divided into two main branches 
corresponding to epidermis and dermis with 46 proteins of epidermis and 90 
mesenchymal proteins of dermis. 
The proteins of different treatment sections were grouped accordingly. 12 percent 
of the proteins identified were statistically significantly differently expressed across 
the treatment sections. Of these differently expressed proteins (DEPs) of epidermis 
2/3 were higher expressed in samples of control sections compared to treatment 
sections with additional dermal stimulus (either with dermal template or with 
cellulose sponge induced granulation tissue). Only one out of thirty, KRT34, of the 
DEPs of epidermis was higher expressed in the ADM group compared to other two 
groups. 
The biggest differences were detected in expression of motor protein axonemal 
heavy chain dynein DNAH10 in epidermis with a 34-fold difference between the 
control sections and granulation tissue sections; here the control sections showing 
the least expression of DNAH10 protein. 
The validation of proteomic results was performed by immunohistochemical 
stainings of same biopsy samples of most differently expressed protein DNAH10 
together with CASP14. The results were similar even though not identical compared 
to results in proteomics confirming the validity of proteomics. 
Of DEPs of dermis the biggest differences in expression were detected in four 
different keratin proteins: KRT1, KRT6C, KRT16 and KRT77. All these proteins 
showed higher expression in the IGT group compared to other treatment sections. 
The induced granulation tissue seemed to increase the expression of those four 
keratins in dermis.  
Collagen 6A2 binds to extracellular matrix proteins, an interaction that explains
the importance of this collagen in organizing matrix components. Here the highest 
expression was found in control group compared to other test groups. 
COL12A1 is a member of the fibril-associated collagens with interrupted triple 
helices (FACIT) collagen family. Type XII collagen is found to be associated with 
type I collagen modifying interactions between collagen I fibrils and the surrounding 
matrix. 
FN1, gene encoding fibronectin, is involved in cell adhesion and migration 
processes including embryogenesis, wound healing, blood coagulation, host defense, 
and metastasis. In both COL12A1 and FN1 the highest expression of the proteins 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.1 GENE EXPRESSION ANALYSES 
In the study III using Ingenuity Pathway Analysis (IPA) software the pathway 
and network analysis were performed for epidermal differentially expressed proteins 
of STSGs of burn patients. Analysis of the upregulated proteins showed showed 
following functions possibly linked to DNAH10: epithelial cell proliferation, hair 
cell differentiation and epithelial barrier formation. 
The promoter regions of DNAH10 were analysed by using TRANSFAC® to 
predict transcription factors of DNAH10. In this analysis and prediction of the best 
three hits for transcription factors yielded following transcription factors: AP-2, 
KLF-6 and ZF-5, which all regulate cell proliferation and differentiation. 
The DNAH10 gene has been shown to have ten splice variants. Six out of these 
transcripts are coding proteins. Two of them, DNAH10-210 and DNAH10-201, are 
coding large dynein proteins (500 kDa) and three of them, namely DNAH10-205, -
207, and -209, code smaller DNAH10 proteins (35-115kDa). Three of transcripts 
yield protein products that include unique peptide sequence 
“LESIFIGGDIRSQLPEEAKKFDNIDKVF”: DNAH10-205, DNAH10-201 and 
DNAH10-210. In our proteomic analysis in mass-spectrometry we also identified a 
unique DNAH10 peptide that could be encoded by a shorter transcript variant 
DNAH10-205.  
The RNA sequencing data of lesional and non-lesional psoriatic skin showed a 
down regulation of DNAH10 in lesional psoriasis whereas in immunohistochemistry 
there was a clear increase in DNAH10 in lesional psoriasis compared to non-lesional 
and healthy control skin (p< 0,0001 between healthy psoriasis skin and psoriasis 
lesion, psoriasis lesion mean 0,1794 ± 0,1147 SD, healthy psoriasis skin mean
0,07966 ± 0,008032 SD, p< 0,0001  between psoriasis lesion and healthy control, 
healthy control mean 0,07267  ± 0,09042 SD).
5.3.2 CELL STIMULATION EXPERIMENTS 
In order to better understand the possible role/ functions and regulation of 
DNAH10 primary human keratinocytes (PHK) were cultured and stimulated with 
different agents.  
A three-hour- treatment of primary keratinocyte cell culture with Mitomycin-C
resulted in increase in expression of DNAH10 compared to non-treated keratinocyte 
cell cultures after 72- hour- culture medium incubation. Mitomycin C is an 
antineoplastic agent blocking DNA synthesis and thereby cell proliferation. 
Cell stimulation of pro-inflammatory cytokines TNF-α and growth factor TGF-
β1 resulted in a decrease in expression of DNAH10 in primary human keratinocytes 
after 24-hour-incubation. TGF-β1 decreased the expression of DNAH10 less than 
TNF-α but their combination showed the strongest decrease in DNAH10 expression.
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Table X. Summary of results of burn patients study III + VSS 
Parameter STSG ADM IGT
VSS 2,5 -> 0,8 2,5 -> 1,3 2,9 -> 0,8
Ki67(MIB-1) ++ + +++
Col IV ++ +++ +
CASP14 +++ ++ ++
DNAH10 + +++ ++


































This research is based on materials retrieved from a prospective study on ten 
patients with third-degree burns. Two different types of materials were used in test 
areas and the purpose was to evaluate if the different wound bed compositions in the 
early healing phase have an effect on wound healing process and/or on the outcome 
of a skin graft. 
Covering the excised burn wound either with a temporary material or with 
dermal components containing permanent material permits a delay in final epidermal 
coverage. This is crucial in cases where there is a shortage of donor sites when re-
harvesting of the sites is inevitable. It is important that these covering materials 
fulfill the requirements of barrier function from outside in. Regarding inside out 
barrier function, preventing the escape of fluids, would be profitable but seldom 
available in temporary dressings. The gold standard is to use STSGs as final covers 
of excised burns even after pre-treatment of the wound bed. Despite the commonness 
of STSG use in surgery, relatively little is known about the wound healing of the 
skin graft at the cellular or molecular level in humans.
6.1 THE EFFECTS OF DIFFERENT TREATMENT 
MATERIALS ON WOUND HEALING AND ON STSGS, 
AND LONG-TERM OUTCOME ONE YEAR AFTER 
SURGERY, STUDIES I & II
The focus of study I was on clinical, histological, and immunohistochemical 
evaluation. In study II, the focus was on the healing of STSGs during transition from 
inflammation phase to proliferation phase and in remodeling phase evaluated with 
image-assisted analysis. 
Viscose cellulose sponge Cellonex™ a by-product engineered by the wood 
industry was used in these studies as a temporary wound cover. It was changed as a 
wound dressing twice before removal and replacement with STSG. The purpose was 
to induce granulation tissue formation on the wound bed to optimize the 
environment for skin grafting. The suitability of the material for wound temporizing 
before harvesting the skin graft was also tested. In previous studies, the material has 
been shown to act as a chemoattractant for cells that are involved in the repair 
process. Even doing so, the cellulose sponge has been shown not to interfere with the 
normal wound healing process (207-210). Chemoattraction of cells into cellulose 
sponge has been explained by absorption of proteins of blood into the material. 
Platelets from the clot secrete cytokines and growth factors attracting inflammatory 
cells to the site (211). When implanted in rodent studies the viscose cellulose sponge 
has been shown to elicit moderate foreign-body reaction. The same cellulose sponge 
material coated with hydroxyapatite was shown to attract circulating hematopoietic 
and mesenchymal progenitor cells in a rodent study (212). 
The other material tested was an acellular dermal matrix (ADM), a dermal 
substitute Integra®. It is a synthetic combination of collagen type I, the most 
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abundant ECM protein in dermis, from bovine hide and glycosaminoglycan 
chondroitin-6-sulfate from shark’s cartilage and on top a polysiloxane membrane 
mimicking epidermis for barrier function. This ADM offers components of natural 
dermal ECM as a template for the migration of the cells and for the ingrowth of 
tissue with vasculature. The host cells are expected to remodel and degrade the 
matrix while simultaneously producing replacing components to achieve ECM with 
closer resemblance to normal skin than to a scar. 
6.1.1 BIOCOMPATIBILITY AND BIODEGRADABILITY 
In order for a material to be biocompatible with the host tissue it should perform 
its desired function without causing adverse effects (213). In these studies the 
materials performed as expected, promoting wound healing and functioning as a 
barrier without causing undesirable effects. In permanent substitutes, the degradation 
time is of great importance. If the matrix is degraded too early the contractile cells 
are released too early causing wound contraction. If the degradation is prolonged the 
foreign-body reaction and macrophages are activated causing inflammation resulting 
scarring (213). ADM used in these studies is stated to be degraded approximately 
within 30 days (Summary of Safety and Effectiveness Data-FDA). Chondroitin-6-
sulfate (C6S) inhibits proteolytic enzymes. It takes part in the binding and regulating 
growth factors. It also influences chemotaxis, migration, hyperplasia, and 
differentiation of cells. C6S in the dermal substitute could reduce biodegradation of 
collagen caused by proteolytic enzymes, which increases physical stability and could 
facilitate the migration of cells from the surrounding tissue into the collagen 
scaffold. (214) Similarly to the study of Jeng et al. (215) in the current study the 
remnants of ADM were suspected to be still visible in samples at 3 months but no 
immunohistochemical staining was preformed to confirm the finding. The viscose 
cellulose sponge used in this study is not intended to be used as a dermal substitute 
in humans due to its slow degradation by non-enzymatic hydrolysis and it eliciting 
foreign-body reactions.
6.1.2 INFLAMMATION 
The mechanism of action of these two materials is almost the opposite in wound 
healing. The cellulose sponge is known to elicit a local inflammatory reaction and 
foreign-body reaction (211) whereas a component of ADM, chondroitin-6-sulfate 
exhibits anti-inflammatory properties. Chondroitin sulfate (CS) has been shown to 
decrease inflammatory signaling by reducing NF-κB pathway activation in 
macrophages and therefore it has been hypothesized that CS could be beneficial in 
diseases with a strong inflammatory component with preliminary evidence of 
improving moderate to severe psoriasis. CS has also been reported to reduce pro-
inflammatory cytokines like IL-6 and IL-1β, as well as inhibiting collagen type I 
degradation by MMP-1 (216). Chondroitin has also been suggested to mask the sites 




In the current studies (I and II), the above-mentioned properties of the materials 
were confirmed. Cellulose sponge treated test areas exhibited the most of all types of 
leukocytes during the time before permanent covering of the wound with STSGs, 
whereas ADM-treated test areas showed the least inflammatory cells.  The low to 
moderate inflammatory cell infiltration to the ADM site is in accordance with other 
studies (217-219). Inflammation was not particularly prominent in any of the test 
areas though. The inflammatory response in cellulose-sponge treated areas may have 
been additionally increased by the possible contamination of the wound bed during 
dressing changes. The prolonged inflammation of the wound bed combined with 
delayed onset of epithelialization has been seen as an unwanted feature in burn 
surgery predisposing to hypertrophic scarring. Bacterial colonization prolonging 
inflammation and stimulating scar formation has been found to be a risk factor for 
hypertrophic scarring with level II evindence.(220).
Both neutrophils and M1 macrophages show antimicrobial activity. Early-stage 
macrophages also control induction of granulation tissue and myofibroblast 
differentiation whereas M2 macrophages have been shown to decrease their 
expression of inflammatory cytokines and increase anti-inflammatory signaling 
(145). In study II, CD163 staining was used to identify M2 macrophages, both M2c 
representing macrophages that suppress proinflammatory cytokines and M2d 
representing regulatory macrophages (221). One week after grafting STSGs onto
cellulose sponge induced granulation tissue (IGT) presented the most M2 
macrophages and the ADM the least of the test groups. This is in accordance with 
findings of total numbers of leukocytes and of macrophages which both had the 
highest counts in the IGT group and the lowest counts in the ADM group of the test 
groups in study I. Especially on days 7 and 14, the cellulose-sponge treated areas 
showed markedly more neutrophils than the other test areas. After permanent 
covering of the wound bed with STSG the wound bed contamination of microbes 
ceased and the barrier function was restored, resulting less triggers for pro-
inflammatory signaling, creating a microenvironment favorable for macrophage 
conversion into the M2 phenotype. Macrophages may alter their phenotype 
according to their microenvironment (222). According to a rodent study of Agrawal 
et al. the shifting from M1 to M2 polarization altered back and forth in the same 
ADM during healing in (223). This shifting back and forth in ADM could not be 
detected in the current study. 
6.1.3 PROLIFERATION PHASE 
Angiogenesis, granulation tissue and revascularization of STSGs 
Angiogenesis in healing wounds is closely associated with the production of 
vascular endothelial growth factor (VEGF), which promotes neovascularization by 
enhancing endothelial cell proliferation (224). Macrophages have a crucial role in 
angiogenesis by producing VEGF-A (221). It has been suggested that M1 
macrophages stimulate capillary sprouting, whereas M2 macrophages assist in vessel 
stabilization through pericyte recruitment (221). Macrophages have been shown to 
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guide and bridge angiogenic sprouts enabling endothelial cell tip fusion or 
anastomosis between two tips and to facilitate the co-operation between pericytes 
and endothelial cells. Macrophages are also able to transdifferentiate into endothelial 
cells, smooth muscle cells and pericytes (225). Mid-stage macrophages have been 
shown to play a role in transition of granulation tissue into scar tissue (145).
Cellulose sponge has been used both in animal experiments and in treating 
traumatic injuries and burns to promote granulation tissue formation (207,226-228). 
The current findings are in accordance with these studies. In study I in hot spot 
counting by Chalkley count, the IGT group exhibited the highest density of 
capillaries of all test areas during days 7 and 14, whereas in the ADM group the 
angiogenesis of the material proceeded more slowly showing the least staining of the 
test groups during days 7 and 14. In all patients, the ADM had vascularized by two 
weeks as had been seen in another study in the acute setting (219), whereas in 
reconstructive cases the vascularization has been shown to take longer (229,230). 
M2 macrophages are known promote angiogenesis, tissue re-modelling, and tissue 
repair. It has been suggested that macrophage influx and angiogenesis are spatially 
correlated (221). In study II the higher incidence of M2 in the IGT also coincided 
with stronger vascular response.
In burn surgery there is a controversy regarding granulation tissue formation. 
Increase in vascularity contributes to a good graft take, but prior studies have 
associated the increased vascularity with high inflammatory cell density and 
eventually skin fibrosis or hypertrophic scaring (231). On the other hand, granulation 
tissue provides an infrastructure for epithelialization (232) and has also been 
suggested to be a source of dermal stem cells (232). There is no clear cut-off point of 
beneficial granulation tissue. We currently rely on clinical judgement and bacterial 
cultures to guide the removal of granulation tissue completing the surgical treatment 
after the primary burn excision. In developing countries the removal of granulation 
tissue in burns is sometimes considered unnecessary (233). A study by Dhar et al. 
found no significant difference in the microbiological profile, graft take, or esthetic 
appearance of the grafts between surgical removal and non-removal of the 
granulation tissue (234). In another study on chronic-burn wound patients, failure to 
remove the granulation tissue had no adverse effects on the graft take. Non-removal 
of granulation tissue was associated with less intraoperative blood loss, less oozing 
of tissue fluids conserving the proteins especially important in malnourished 
patients, and reduced time for hemostasis (233).  
Graft take and ADM take 
Before the ingrowth of vasculature took place there was no supply of oxygen and 
nutrition into the ADMs and STSGs other than through imbibition (fluid absorption) 
of plasma accompanied with sporadic cells. The graft survival and graft take relies 
on the restoration of perfusion. Despite the commonness of STSG use, the 
physiological (re)vascularization process is poorly understood (156,235). It is not 
fully clear how the revascularization of the skin graft occurs, whether the endothelial 
cells of the wound bed migrate and populate the graft, or how the cells from the graft 
intrude into the wound bed. According to animal studies, the current view supports 
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the idea of ingrowth of newly formed blood vessels from the wound bed into the 
graft, which are subsequently connected to the existing vasculature by inosculation 
“plug-in”. The perfusion of graft capillaries in mice has been seen by intravital 
microscopy already on day 3 and the restoration of circulation by day 5 (235). In the 
current study, the timely graft take was good irrespective of the treatment area. No
complications preventing graft take like hematoma, seroma, or infection, were 
detected. One STSG on ADM was lost due to erroneous upside-down placement of 
the STSG and it was successfully replaced one week later. 
ADMs were vascularized by angiogenesis from the wound bed. Angiogenesis 
into the ADM seemed to be slower than the formation of granulation tissue with 
abundant vascularity on the cellulose sponge-treated test areas but all ADMs 
vascularized well within fourteen days. This is in accordance with other studies in 
acute settings (219), whereas in later reconstructions the vascularization is 
decelerated until four weeks (230) or later. This time delay interval before 
vascularization of a skin substitute limits its use and predisposes the material and 
wound bed to infection. On the other hand in many situations the time delay is 
appreciated and this wound temporising can be continued for weeks, even months by 
absence of infection while awaiting the possibility to re-harvest the donor sites.
Some current dermal substitutes permit STSG transplantation simultaneously relying 
on the graft imbibition through the substitute but the risk of delay of plugging in of 
STSG and thereby the risk of graft loss is increased.  
In study II, in image analysis one week after transplantation the STSGs on IGT 
showed the most stained total area and the largest average size of vessels with 
significant difference compared to the other test areas. In this image analysis the 
vessel density was also higher in cellulose-sponge-treated areas than in other test 
areas, but the difference remained non-significant. This all suggests that the cellulose 
sponge-induced active matrix of granulation tissue is supportive microenvironment 
for graft take and the proliferative phase of wound healing. 
Epithelialization  
All test areas were covered with unmeshed equally thick STSGs within two 
weeks after burn-wound excision and all grafts took (except one mentioned earlier, 
which was successfully re-grafted one week later). Papillary fibroblasts in 
granulation tissue are found to support epithelialization and formation of BM, and to 
produce less collagen and more proteoglycans resulting in improved differentiation 
and stratification of epidermis (34). In these studies all STSGs contained papillary 
dermis with fibroblasts but the granulation tissue in each test group was different. 
One year after excision the differentiation evaluated by differentiation marker 
CASP14 (study III) was higher on the control sites compared to the other test areas. 
In numbers of cell layers, no differences between the test groups were detected.  
Keratinocyte proliferation  
One week after grafting, the keratinocytes in STSGs on IGT proliferated 
markedly more than on other test groups with highly significant differences. The 
increased proliferation of keratinocytes on IGT corresponded and coincided with 
higher numbers of M2 macrophages as well as with increased vascularity compared 
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to other test areas. The STSGs on IGT likely had good supply of oxygen and 
nutrition as well as the supply of inflammatory cells especially 
monocyte/macrophages from circulation in addition to local tissue macrophages. 
Rich vascularity also guaranteed an adequate amount of endothelial cells to produce 
growth factors in conjunction with macrophages and fibroblasts of granulation tissue 
to promote keratinocyte proliferation. Factors known to promote keratinocyte 
proliferation include growth factors and cytokines like: IL-1, -6, and -8; TGF-α;
GM-CSF; and amphiregulin (236). These factors are produced by keratinocytes, but 
partly also by macrophages, endothelial cells, and fibroblasts. The constant cross-
talk between keratinocytes, fibroblasts, inflammatory cells, and endothelial cells is 
vital in order for wound healing to proceed properly. By three months there was no 
difference between the test areas in proliferation of keratinocytes since the 
inflammation ceased with decreased secretion of growth factors and cytokines. In 
study III, at one year the keratinocyte proliferation was again significantly higher in 
IGT than in ADM treatment sites. The reason for this is unclear. There is a wide 
variety of possible explanations such as chronic irritation or inflammation (237),
differences in epidermal barrier function, in T-memory cells or if it was due to 
epidermal stem cells remembering earlier stronger inflammation with the changes in 
their chromosomes, overproduction of growth factors, abnormal response to 
lymphokines and cytokines, disturbances in IL-1 cascade (238), tissue stiffening 
(239), abnormal keratinocyte proliferation and differentiation, dermal infiltration of 
immune cells, increased capillary density and wide capillaries with increased 
permeability enhancing recruitment of inflammatory cells (240), histamine (241) 
which were not examined in this study.  
Changes in BM 
Even though the re-epithelialization was not an issue in these studies changes in 
BM composition were discovered. Collagen type IV in BM was found to be low or 
non-existing in most of the samples by day three and up to 3 months, at which time 
its’ expression was lowest. By 12 months, collagen type IV was almost a continuous 
line in most of the samples. The STSGs of ADM group showed the most staining of 
collagen type IV and the STSGs on IGT the least staining at twelve months 
compared to the other test areas. Immunohistochemical staining of laminin-5 was 
also tested and yielded no staining results. Either the antibody tested did not work in 
the samples, or there was no laminin-5 present. The reason for missing or decreased 
type IV collagen in BM of STSGs after transplantation is unclear. The possible 
explanations could be either that the dermatome affects the BMs during the 
harvesting of STSGs via an unknown mechanism, or that this is the natural course of 
healing of STSGs. It is known that upon tissue injury pro-inflammatory and pro-
fibrotic mediators such as IL-1, IL-6, TNF-α, and TGF-β are released (128). As a 
result, secretion of metalloproteases like MMP-2 and MMP-9 is increased in 
conjunction with migration of macrophages to the site of injury releasing MMP-12 
which all degrade type IV collagen. Fragmented BM allows entry and exit of 
inflammatory cells like macrophages, and fibroblasts forming fibrotic tissue. 
Moreover, the breakdown of BM and increased expression of TGF-β1 have been 
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suggested to promote epithelial-mesenchymal transformation (242) and likely also 
contribute to myofibroblasts transformation increasing scar formation. MMP-2-
mediated proteolytic alteration of type IV collagen is important for the migration of 
macrophages and fibroblasts (128). In studies I and III, an inverse relationship was 
observed between keratinocyte proliferation evaluated of MIB1 and expression of 
BM collagen type IV between the different treatment areas. One possible 
explanation could be that the proliferating cells produce growth factors and 
cytokines that induce the release and synthesis of proteases degrading collagen type 
IV simultaneously. Horch (243) and Langdon (244) both observed the disappearance 
and later re-appearance of BM after skin grafting in different settings. 
Fibroblast proliferation  
In study I the numbers of fibroblasts was highest at three weeks after operation 
and at 3 month follow-up the control group showed an increased amount 
myofibroblasts compared to other test groups, but the differences were not 
significant. AMD had almost no proliferating fibroblasts on d7 and d14. In study II, 
one week after grafting, the dermal cells of the superficial dermis proliferated more 
in the groups of pre-treated wound beds compared to the control group suggesting 
that the new additional vascularized ECM promoted fibroblast proliferation. At three 
months, the situation had changed to just opposite. The superficial fibroblasts in the 
control group proliferated markedly more (nearly ten times more) and approximately 
twice as much as one week after grafting. The reason for the late increase of dermal 
cell proliferation of the control site is unclear.  
Remodeling  
Myofibroblasts and wound contraction 
None of the test areas showed major contraction, but the measurements were not 
accurate enough to draw any conclusions. Compared to the other test groups, the 
control group showed the most myofibroblasts after excision, between day 3 and 3
months. In addition to inflammation, other factors promoting myofibroblast 
activation also increase the risk for scarring. Inflammatory signals and profibrotic 
growth factors activate fibroblasts (245). It may well be that ADM decreases wound 
contraction as suggested by others by attracting myofibroblasts to bind to the 
scaffold instead of binding to surrounding tissue to contract the wound and by 
binding profibrotic TGF-β by GAGs in the scaffold (246,247). 
The neodermis of ADM has been shown become thicker during early remodeling 
and then gradually decrease in thickness as the maturation proceeds over a few 
months (229). In study I the thickness of neodermis was still increased both in ADM 
and the control site at one year whereas the increase of the thickness of IGT halted 
already at three months. 
In normal wound healing after re-epithelialization, myofibroblasts disappear via 
apoptosis one to two weeks after injury. The restoration of well-established 
epidermis plays a role in inhibiting wound contraction. The faster the epidermis is 
regenerated, the more wound contraction is suppressed, whereas delay in re-
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epithelialization may result in hypertrophic scarring. Early grafting with unmeshed 
sheet grafts has been shown to reduce granulation tissue formation and scarring, and 
to result in optimal functional and cosmetic outcomes (172) as in this study. In 
studies I and II, the timing of re-epithelialization failed to impact additional scar 
formation, but the degradation of collagen type IV of BM may have contributed to 
scar formation by promoting epithelial-mesenchymal transdifferentiation.
Clinical scar assessment- cosmetic and functional outcome 
In this study, the original Burn Scar Index, the Vancouver Scar Scale (VSS) was 
used.  The scale was later slightly amended in regard to pigmentation. Occupational 
therapists were accustomed to assessing scars with the original scale and therefore it 
was used. In clinical assessments with VSS, the scar quality seemed to improve the 
most in IGT group and the least in ADM group. In total scores, the ADM group 
performed slightly worse than the other groups, but the differences between the test 
groups were not significant. There were both palpable and visual differences 
between treatment sites in some patients but there were no clear trends and none of 
the treatment sites seemed to have a preferable outcome. Since the number of 
patients in the study is rather low, the interpretation of results may not be reliable 
and must be considered with caution. 
In contrary to many other studies (248,249) that employed the assessment 
methods used here, ADM did not seem to perform better than STSG alone as a 
control site.The one-year time point may have been too early to detect final 
differences especially for ADM-treated areas since the maturation of ADM may 
have still been in progress. The assessment methods were also subjective and 
therefore not optimal to detect fine differences. Nonetheless, no major or clinically 
relevant differences were detected. In earlier studies of ADM reconstructions, better 
outcomes have been achieved in comparison to the situation prior to reconstruction 
(229,249-252). In an objective evaluation study using a Cutometer, AMD was 
claimed to be more pliable and elastic, a parameter not measured in VSS (248).
The main hypothesis was that the use of ADM would result in better long-term 
outcome, both functionally and cosmetically. The hypothesis could not be proven 
using VSS assessment and histological evaluations. In study I the ADM test group 
did not perform markedly better than the other test groups. Nonetheless, ADM also 
performed no worse than other materials, too. Histological and 
immunohistochemical differences at the one-year time point were minimal between 
the test groups.  
VSS has been criticized for poor inter-rater reliability, non-specificity, deficiency 
in objectivity, not taking patients’ symptoms into account, but also having no 
generally accepted interpretations of the scores (181) e.g. which scoring would 
define a hypertrophic scar.  As in the study of Heimbach et. al., patients preferred 
ADM due to less itching compared to STSG, allograft, xenograft and synthetic 
dressings, a symptom not taken into account by VSS (249). All of these claims 




6.2 THE LONG-TERM EFFECTS OF DIFFERENT EARLY 
WOUND-BED TREATMENT MATERIALS DETECTED IN 
PROTEOMICS AND REFLECTED TO PSORIASIS, STUDY 
III 
Study III focused on the long-term outcome of protein level analysis. 
To examine and to compare the long-term effect of three different dermal 
compositions on STSGs at the protein level, one year after surgery of a deep burn 
wound, mass-spectrometry, MaxQuant 1.4.0.8 software and UniProt human database 
were used to identify and to quantitate proteins. 
6.2.1 PROTEOMIC FINDINGS IN SKIN SAMPLES OF BURN PATIENTS 
The number of proteins identified in skin varies depending on the methods used. 
According to the Human Protein Atlas www.proteinatlas.org, transcriptomic analysis 
has identified 14857 proteins in human skin (status 12.1.2020). Proteomic 
techniques may be more sensitive and more precise than conventional methods, but 
the meaning and the significance of the findings often remain unclear. Proteomic 
analyses have been found that the proteins in different areas of skin vary, e.g. breast 
skin has some different proteins compared to skin of the leg (253). In study III, 481 
proteins were identified by untargeted, non-labelled proteomics from skin samples 
taken at one-year follow-up. Significantly different expression between the test-
groups was found in 12% of the proteins identified, 30 proteins of epidermis, and 24 
proteins of dermis. The most surprising finding was in a protein in the epidermis 
with a 34-fold difference between the control group and the IGT group, namely in a 
motor protein axonemal heavy chain dynein 10 (DNAH10). 
DNAH10 
DNAH10 protein has not been listed in the Human Protein Atlas 
https://www.proteinatlas.org/search/keratinocytes (status checked 12th January,
2020) as being detected in keratinocytes. Dyneins in motile cilia function in cell 
signaling and driving ciliary motility, inner arm dyneins regulating the beating 
pattern and frequency DNAH10 belonging to inner arm dyneins. In mRNA 
expression of DNAH10 level is very low, however the proteomics and 
immunohistochemistry employed in this study detected protein expression in skin. 
The immunoreactivity was localized to keratinocytes and sweat glands (glandulae 
sudoriferae). In the literature, DNAH10 is assigned as an inner arm dynein, which 
regulates the beating pattern and frequency. The current results, however, suggest 
cell-cycle- and cytokinedependent cytoplasmic expression of DNAH10. Due to the 
preliminary nature of the current study’s results, care should be taken in their 
interpretation. Some of the study limitations are listed at the end of this chapter. 
In phylogenetic studies, DNAH10 has been linked to the axoneme of motile cilia 
as an inner arm heavy chain force-generating motor protein taking part in bending 
microtubule in axoneme. It has been identified in respiratory cilia of airway 
epithelium and in skin in sweat glands. In this study, immunohistochemical stains 
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demonstrated DNAH10 expression in keratinocytes as well as in sweat glands. 
Nonetheless, almost all basal keratinocytes have been found to carry a primary 
cilium both in normal and in psoriatic skin. The ciliary structure is progressively 
reduced in keratinocytes towards the surface and no primary cilia were found in the 
granular layer (76). In the primary cilia of keratinocytes, no dynein arms were 
observed. Primary cilia have been found to be less common in mitotic than in non-
mitotic tissue and they have been suggested to be involved in the regulation of 
mitosis (76). The major tasks of primary cilia include the recognition of extracellular 
signals, such as growth factors, hormones, and nutrients (240). The cilium membrane 
contains numerous receptors, ion channels, and signaling-pathway components, such 
as Shh and Wnt receptors. Primary cilia are important in signal transduction during 
development, cell migration, the cell cycle, and apoptosis. Ciliogenesis is promoted 
by various cellular stresses, such as UV radiation, heat shock, actin destabilization, 
loss of mechanical stresses, and serum starvation. Ciliogenesis is highly linked with 
the arrest of cell growth and proliferation. Differentiation of stem cells requires the 
presence of primary cilia and is associated with intra flagellar transport. The absence 
of primary cilia inhibits the differentiation of mesenchymal stem cells.(254) 
OTHER PROTEOMIC FINDINGS 
In epidermis, seven out of nine of the most differently expressed proteins (DEPs) 
were most expressed in the control group, whereas the same number of DEPs were 
expressed the lowest in the ADM group. The functions of these proteins vary and 
associations between these proteins cannot (yet) be described. The expression of 
KRT34, a type I hair keratin heterodimerizing with type II keratins to form hair and 
nails, seemed to be increased in pre-treated groups compared to controls, suggesting 
that additional new ECM under the STSG may create a more supportive 
environment for hair follicles than STSG alone. 
In dermis, four out of seven of the most differently expressed proteins were 
keratins, most likely from hair follicles, all expressed higher in the IGT group 
compared to other groups. The presence of these keratins in hair follicles has been 
described in various studies (253,254). KRT77, also known as KRT 1b, is expressed 
in the skin and eccrine sweat glands. KRT6, 16, and 17 are normally not expressed 
in the interfollicular epidermis but they are rapidly induced in response to various 
triggers e.g., wounding, infection, as well as in the setting of chronic 
hyperproliferative diseases e.g., psoriasis and cancer (20,21). The induction of 
KRT6/16/17 occurs at the expense of the KRT10 and KRT1 keratin pair, which 
inhibits cell cycle progression and promotes differentiation in normal keratinocytes. 
6.2.2 VALIDATIONS 
To validate the correct laser dissection of different skin layers, all proteins 
identified in mass-spectrometry were clustered with Gene Cluster 3.0 software which 
resulted in two main branches corresponding to proteins of the epidermis and dermis. 
The validation of proteomic results was gained from IHC samples for DNAH10 and 
CASP14. The results of validation were not identical as expected due to different 
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methodology, but were similar to proteomic findings. DNAH10 was expressed the 
least in the test areas of control sites. The results of CASP14, a differentiation 
marker of keratinocytes, also corresponded with the results of proteomics. The 
control sites exhibited the highest expression of CASP14 of all test areas. The low 
number of patients studied limits the reliability of the results. Since the study was 
designed as comparison within patients also, the patients served as their own 
controls.  
6.2.3 IPA AND TRANSFAC® ANALYSES 
All DEPs between different test groups were analyzed using Ingenuity Pathway 
Analysis (IPA) software pathway and network analysis to discover biological 
networks associated with these results from proteomics. Proliferation, differentiation, 
and barrier function were found to be significantly associated with the reported 
findings.  
TRANSFAC® analysis provided likely transcription factors analyzed by 
promoter regions. The promoter region of DNAH10 was utilized to predict the 
binding sites for transcription factors. Within this promoter region, the most binding 
sites were found for transcription factors KLF6, AP-2, and ZF-5, all regulating cell 
proliferation and differentiation (255-260). Taken together, these associations linked 
DNAH10 with keratinocyte cell cycle control.  
6.2.4 DNAH10 MRNA SPLICE VARIANTS  
Ten mRNA splice variants have been identified as transcribed from the DNAH10 
gene. Six of these yield protein products. No DNAH10 gene expression was detected 
in the mRNA sequencing studies in psoriasis patients, suggesting that DNAH10 
protein expression might be controlled at a post-translational level. The rather large 
size of the DNAH10 protein (515 kDa) may contribute to slow cycling and 
expression changes of the protein but the size of the protein varies by the splice 
variants: the transcripts DNAH10-210 and DNAH10-201 produce large proteins of 
500 kDa, whereas the transcript variants DNAH10-205, −207, and −209 yield 
smaller proteins ranging from 35 to 115 kDa. The unique DNAH10 peptide 
identified by mass-spectrometry could be encoded by a shorter transcript variant 
DNAH10-205. This transcript may be subject to nonsense-mediated decay (NMD), a 
surveillance system serving quality control of newly synthetized mRNA (261). There 
are many different ways that the mRNA can escape NMD quality control (262). 
DNAH10-205 may escape and contribute to the NMD pathway to DNAH10 or 
DNAH10-205 expression in the long-term memory response. 
Several transcripts are known to be transcribed from the DNAH10 gene and the 
protein products may also be subject to several kinds of post-translational 
modification. These processes are likely contributors to the expression patterns of 
DNAH10 tissue, cellular, and subcellular levels. The current discovery provides 
DNAH10 expression with a new clinical association with which its expression and 
regulation can be studied further in preclinical and clinical settings. 
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6.2.5 DNAH10 EXPRESSION IN INFLAMMATORY SKIN PATHOLOGY 
PSORIASIS  
Psoriasis and wound healing share several features. Clinically, both patient 
groups suffer from similar symptoms, such as dry skin that may crack and bleed, 
itching, and burning sensation. Both patients with psoriasis and burn patients with 
STSGs also show decreased or defective barrier function of skin at least up until one 
year after injury. Inflammation and epithelial hyperproliferation are characteristic 
landmarks for both, as well as angiogenesis/vascularization. All these processes are 
also influenced by dermis. Its immune cells, including skin-resident T cells, dendritic 
cells, and fibroblasts, secrete cytokines and chemokines that modulate these 
processes.  
Biological processes such as proliferation, differentiation, and barrier function 
are significantly associated with the observation of DNAH10 in STSGs of burn 
wounds. This presents a remarkable resemblance to the pathological features of 
psoriasis (263-265) and previous work on psoriasis and keratinocytes (206,266,267);
DNAH10 protein expression is also affected in active psoriatic epidermis. As dermal 
inflammation is also present at early stages of psoriasis-plaque formation, the 
increased protein expression of DNAH10 found in this study in the active sites of 
psoriatic inflammation, thus further links the protein regulation of DNAH10 with 
inflammation; and its likely dysregulation in psoriasis. 
This hypothesis was tested on samples collected using dermatome (thus 
superficial, epidermis-enriched and similar in thickness to STSGs) from patients 
with psoriasis. These samples have been mRNA-sequenced previously, thus ample 
data was available to evaluate dynein expression at the mRNA level (266,267). The 
RNA sequencing data of lesional and non-lesional psoriatic skin showed a down 
regulation of DNAH10 in lesional psoriasis. The IHC provided clear evidence to 
support the hypothesis of increased expression of DNAH10 protein in the epidermis 
of psoriatic lesions compared to unaffected skin from the same individuals and to 
healthy controls. The tendency towards an aberrant dual pattern of DNAH10 staining 
across the depth of the epidermis as observed in normal control epidermis, psoriatic 
epidermis, and during wound healing, suggests that DNAH10 expression is activated 
at specific times during keratinocyte differentiation. The expression of axonemal 
dyneins has been linked to cell differentiation and correlated with the appearance of 
a ciliated phenotype (268). 
6.2.6 DNAH10 IN CELL STIMULATION EXPERIMENTS 
This study sought to confirm the inverse correlation of proliferation and 
expression of DNAH10 in keratinocytes by cell stimulation experiments of cultured 
primary human keratinocytes. Keratinocytes were stimulated with Mitomycin-C, a 
cell cycle inhibitor blocking DNA synthesis. This resulted in increased DNAH10 in 
the inhibited keratinocytes compared to controls. Protein p53, the “guardian of the 
genome,” has been associated with dyneins. Giannakakou et al. have suggested that 
dyneins together with functional microtubules transport p53 and facilitate its 
accumulation in the nucleus after DNA damage (269). As a result of cellular stress 
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such as hypoxia or DNA damage, p53 accumulates in the nucleus, and activates and 
functions as a transcription factor. Treatment with Mitomycin-C may cause stress for 
keratinocytes. In this study, it seemed that DNAH10 was accumulated into the 
cytoplasm of keratinocytes. Other possibilities to explain the accumulation of 
DNAH10 might include rapid increased synthesis or it was not degraded in that time 
frame, suggesting that DNAH10 would be involved in proliferation. It could also be 
that DNAH10 was transported into dynein arms of cilia to be preassembled in the 
cytoplasm before transport into cilia (94).
Further investigations are needed to find out whether the DNAH10 accumulated 
into the cytoplasm originated from cilia (primary, motile, or nodal), or from 
intraflagellar transport or from cytoplasm. 
The effect of the pro-inflammatory mediators TNF-α and TGF-β1 on DNAH10 
expression in keratinocytes was examined. TNF-α is a pro-inflammatory cytokine 
produced by human keratinocytes. As primary inflammatory response to injury or 
other inflammatory stimulus, keratinocytes produce IL1α and TNF-α (270). In 
keratinocytes, TNF alpha regulates immune and inflammatory responses, and also 
tissue remodeling, cell motility, cell cycle, and apoptosis (271). In addition to 
activating keratinocytes TNF-α and IL1α also activate dermal fibroblasts and 
endothelial cells and attract neutrophils, macrophages, mast cells, and skin-specific 
memory T-cells. TNF-α also promotes tissue repair by inducing synthesis of BM 
components and collagen-degrading proteases, and it induces actin cytoskeleton 
regulators and integrins, enhancing keratinocyte motility and attachment. TNF-α
may also sensitize or prime keratinocytes to other stimuli like cytokines and growth 
factors to react quickly (271). TNFα is known to be one of the main executor 
cytokines in psoriasis. 
TGF-β1 is known to have both pro-inflammatory and anti-inflammatory 
properties affecting different immune cells thereby regulating the inflammatory 
response (270). TGF-β1 is also needed for maturation and migration of LCs. LCs 
and macrophages activate T cells to proliferate and differentiate into 
memory/effector T cells. As the healing progresses the inflammation is suppressed 
by TGF-β1, which has inhibitory effects on both innate and adaptive immune cell 
function (270). TGF-β1 is also known to inhibit keratinocyte proliferation, whereas 
it promotes keratinocyte migration. Blocking of TGF-β1 signaling has been shown to 
result in keratinocyte hyperproliferation.  
Cell stimulation by pro-inflammatory cytokines TNF-α and growth factor TGF-
β1 resulted in decreased expression of DNAH10 in primary human keratinocytes 
after a 24-hour-incubation. TGF-β1 decreased the expression of DNAH10 less than 
TNF-α but their combination showed the strongest decrease in DNAH10 expression 
in keratinocytes. The findings indirectly suggest that the decrease in keratinocyte 
DNAH10 after stimulation with pro-inflammatory and/or pro-fibrotic signals 
resulted in either increased consumption or decreased synthesis of DNAH10 in 
keratinocytes. This warrants further studies.  
Cells residing in the epidermis have been shown to maintain signatures at the 
molecular level (these could be epigenetic modifications on DNA, or changes in 
RNA or protein expression) in response to inflammatory injury and wound healing. 
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The cells currently associated with this type of memory include CD8+ tissue-
resident T-cells and Treg cells. The work reported here associates keratinocytes with 
this type of long-term molecular persisting response after wound healing, and 
especially with the formation of dermis.  
Limitations of Study I and II to draw conclusions  
Test areas were small and close to each other, thus the cellular signaling of the 
neighbor area could have affected the results. The number of patients is quite small 
even though all the treatments were compared with-in the same patient. The clinical 
scar assessment tool was too crude to detect fine differences between the treatment 
groups and, due to the tool itself, it was subjected to some degree subjectivity. The 
inter-rater differences were sought to be reduced to a minimum by limiting the 
number of raters and by having the same person throughout the study. The 
occupational therapist was a part of team that took care of the patients so any kind of 
blinding was impossible. In the early phase before covering the wound bed with 
STSGs the differentiation between the test sites was obvious. VSS does not actually 
measure patients’ functional restrictions caused by the scar, nor does it evaluate 
patients’ symptoms such as pain and itching, which have significant effects on 
quality of life. Nonetheless, many of the scar assessment scales and tools have been 
validated by comparing their results to VSS. 
Limitations of Study III 
The location of where the skin graft was harvested was not taken into account, 
which might have affected the results, but within each patient the grafts were taken 
from the same location to cover ADM and IGT areas.  
The use of proteomic techniques is not easy in skin tissue due to an abundance of 
protein cross-linking and high lipid content making isolation and digestion of 
proteins for analyses challenging (192). The method may also be too sensitive and 
the interpretation of results of clinical work is difficult to make. 
Especially the discovery of DNAH10 relied on a single specific peptide. 
Conventionally in proteomics, proteins identified by a single peptide are filtered out 
of the results. The dramatic change in expression of DNAH10, however, drew 
interest and it was chosen to be validated using immunohistochemistry. The 
limitation of IHC results is that they rely on use of a single antibody and the lack of 
use of blocking peptide in the experiments. These issues will be addressed in future 
experiments. The antibody was validated in the Human protein atlas at the time and 
showed specificity to only its own antigen in a protein array. The discovery of 
DNAH10 must also be validated in the fresh skin samples in the future as well as its’ 
functional associations should be further studied using molecular biology tools such 




 CONCLUSIONS  7.
This study of treating deep burn wounds after excision, with three different 
materials, yielded the following conclusions: 
Study I & II 
- The early wound healing was affected by different covering materials: 
Cellulose sponge treatment promoted inflammatory response, whereas ADM 
presented a more suppressed inflammatory response. Early moderate 
inflammation had no adverse long-term effects. 
- Granulation tissue induced by cellulose sponge provided a supportive 
environment for a skin graft.  
- The use of ADM possibly retards early wound healing accompanied with 
decreased and/or delayed fibroplasia.  
- The differences in early wound healing failed to affect the clinical functional 
or cosmetic outcome after one year. ADM performed equally well after one 
year compared to the other materials tested. The main hypothesis was proven 
to be wrong. 
- Both ADM and cellulose sponge are useful tools if wound temporising before 
skin graft re-harvesting is needed. 
Study III  
- Persistent differences in the expression of certain tissue-specific proteins, 
depending on the early wound bed treatment, shows that early treatment 
influences subsequent tissue proteome, although it may remain below the 
macroscopic phenotype. 
- The finding of DNAH10 in keratinocytes is a novelty that has not been 
described previously and fails to fit into the categories of functions and 
locations of dyneins described previously. DNAH10 has been described to be 
a heavy chain two-headed inner-arm dynein found in motile cilia, but motile 
cilia have not been identified in keratinocytes.  
- DNAH10 was found to be present in primary human keratinocytes in clinical 
patient material in the skin of burn patients, in psoriatic lesions, and the level 
of DNAH10 in cultured primary keratinocytes was modulated by mitomycin-
C, TNF-α or TGF-β1, and a combination of the latter. Long-term persistent 
epidermal DNAH10 expression was associated with transient regenerative 
and inflammatory dermal signaling, and DNAH10 expression is increased in 
inflamed psoriatic skin. These discoveries associated epidermal protein 
expression of DNAH10 selectively on initially dermis-manipulated sites still 
one year after the intervention, and linked DNAH10 with dermal epidermal 




 FUTURE PROSPECTS 8.
This thesis provides an example of the role and value of objective comparative 
studies of different treatment modalities through the intra-patient controlled study 
protocols used here. More objective comparative studies of different treatment 
modalities for burns treatment are needed to be able to provide patients with the best 
evidence-based care. It would be important in the future to be able to compare the 
results between different centers also internationally and also for developing the 
quality of care in terms of patient-centered care and the whole quality of care for 
burn patients.  
It seems that some long-term memories of past events like inflammation during 
wound healing of a STSG are sustained in cells, reflecting their ECM environment. 
Although there is no ongoing inflammation in the burn-patient samples, “the 
inflammation-experienced memory,” which is based on DNA chromatin changes, 
maintains DNAH10 expression. It remains unknown whether these possibly 
epigenetic changes may show decades later in skin function, for example via 
transepidermal water loss, transepidermal resistence, or amount of filaggrin in the 
epidermis. The expression of axonemal dyneins has already been linked to cell 
differentiation and correlated with the appearance of a ciliated phenotype. The 
results described here indicate a need for elucidating the roles of primary cilia and 
the axoneme in the epidermis and the functional role of the axonemal dyneins during 
epidermal differentiation. This eluciadation will increase understanding of the 
intricate signaling networks and signaling pathways orchestrating the formation and 
integrity of the skin. Research is especially warranted for understanding the role and 
expressional control of this signaling machinery after wound healing. It would also 
be of great value to investigate DNAH10 expression in experimental animal models,
as well as to further elucidate the expression patterns of DNAH10 using in vitro 3D 
epidermal constructs allowing for genetic manipulation, gene overexpression, and 
knock-outs. Moreover, the contributions of the various gene products and putative 
cleavage protein products of DNAH10 should be studied in more detail. According 
to the preliminary data presented in this thesis, the transcriptional, post-
transcriptional, translational, and post-translational regulation of DNAH10 seems to
be of extreme interest when further studying the role of this specific dynein in cell 
biology and different pathologies. 
We do not know yet enough about the role and regulation of DNAH10 in 
physiological or pathophysiological contexts. However, the results associating 
DNAH10 protein with an epidermal delayed response to wound healing as well as 
psoriasis suggest it indeed could serve a significant biological role. In order to be 
able to have a closer look at the intracellular level of regulation, we need to build 
specific yet simple research methodology. RNA sequencing and various protein level 
tools could provide some answers. Since the low Mw DNAH10 proteins are 
detected, also by us using Western Blotting, in keratinocytes although current 
evidence suggests negligible differences in mRNA expression, expressional 
regulation was considered to occur at the post-translational level. Furthermore, also 
the high Mw species of DNAH10 is abundantly detected in keratinocytes. Given the 
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experimental challenges like antibody specificity, the expressional regulation of 
DNAH10 low Mw species was considered to occur at a post-translational level. It 
will be extremely interesting to determine at which level the regulation actually 
occurs. Sensitive and specific RNA and protein methodologies should be used. It
will also be interesting to determine whether the proteolytic enzyme activity 
associated with keratinocyte differentiation affects DNAH10 processing. For 
example, there are putative MMP-specific enzyme cleavage sites on the high Mw 
DNAH10 that can yield the low Mw species. 
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